Advertisement

Uroonkologie pp 331-369 | Cite as

Nierenzellkarzinom

  • Gerhard Jakse
  • Axel Heidenreich
  • Marcus Schenck

Zusammenfassung

Mehr als 85% aller bösartigen Nierentumoren sind Nierenzellkarzinome. Sarkome, Nephroblastome, Lymphome und Metastasen anderer Organtumoren sind selten, aber differenzialdiagnostisch zu berücksichtigen

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Aass N, De Mulder PHM, Mickisch GHJ, Mulders P, van Oosterom AT, van Poppel H, Fossa SD, de Prijck L, Sylvester RJ (2005) Randomized Phase II/III trial of Interferon Alfa-2a with and without 13-cis-retinoic acid in patients with progressive metastatic renal cell carcinoma. The European Organisation for research and treatment of cancer Genito-Urinary Tract Cancer Group (EORTC 30951). J Clin Oncol 23:4171–4178CrossRefGoogle Scholar
  2. Abukora F, Nambirajan T, Albqami N, Leeb K, Jeschke S, Gschwendtner M, Janetschek G (2005) Laparoscopic nephron sparing surgery: evolution in a decade. Eur Urol 47:488–493PubMedCrossRefGoogle Scholar
  3. Ahrar K, Martin S, Wood CG, Wallace MJ, Gupta S, Madoff DC, Rao S, Tannir NM, Jonasch E, Pisters LL, Rozner MA, Kennamer DL, Hicks ME: Percutaneous radiofrequency ablation of renal tumors: technique, complications and outcome. J Vasc Interv Radiol 2005; 16: 679–688PubMedGoogle Scholar
  4. Akubakr YA, la-Hsu C, Redman B (1994) Spontaneous remission of renal cell carcinoma: a casse report and immunological correlates. J Urol 152: 156–157Google Scholar
  5. Alexander RB, Linehan WM (1993) Editorial comment. J Urol 150: 1390Google Scholar
  6. Althausen P, Althausen A, Jennings LC, Mankin HJ (1997) Prognostic factors and surgical treatment of osseous metastases secondary to renal cell carcinoma. Cancer 80: 1103–9PubMedCrossRefGoogle Scholar
  7. Alves A, Adam R, Majno P et al (2003) Hepatic resection fo metastatic renal tumors: is it worthwhile? Ann Surg Oncol 10: 705–710PubMedCrossRefGoogle Scholar
  8. Amato RJ, Morgan M, Rawat A (2006) Phase I/II study of thalidomide in combination with interleukin-2 in patients with metastatic renal cell carcinoma. Cancer 106(7): 1498–1506PubMedCrossRefGoogle Scholar
  9. Amato RJ (2000) Chemotherapy for renal cell carcinoma. Semin Oncol 27: 177–186PubMedGoogle Scholar
  10. Amato RJ (2003) Thalidomide therapy for renal cell carcinoma. Crit Rev Oncol Hematol 46: 59–65CrossRefGoogle Scholar
  11. Amato RJ, Harris P, Dalton M, et al. (2007) A phase II trial of intrapatient dose-escaleted sorafenib in patients (pts) with metastatic renal cell cancer/MRCG). Proc Am Soc Clin Oncol J Clin Oncol 25: 5026Google Scholar
  12. Amedola MA, King IR, Pollack HM, Gefter W, Kressel HY, Wein AJ (1990) Staging of renal carcioma using magnetic resonance imaging at 1.5 Tesla. Cancer 66: 40–44CrossRefGoogle Scholar
  13. Anast JW, Stoller ML, Meng MV, Master VA, Mitchell JA, Bassett WW, Kane CJ (2004) Differences in complications and outcomes for obese patients undergoing laparoscopic radical, partial or simple nephrectomy. J Urol 172 (6 Pt 1): 2287–91PubMedCrossRefGoogle Scholar
  14. Anderson CM, Pusztai L, Palmer JL, Cabanillas F, Ellerhorst JA (1998) Coincident renal cell carcinoma and non Hodgkin’s lymphoma: the M.D. Anderson experience and review of the literature. J Urol 159: 714PubMedCrossRefGoogle Scholar
  15. Andrews DW, Scott CB, Sperduto PW et al. (2004) Whole brain radiation therapy with or without sterotatic readiosurgery boost for patients with one the three brain metastases. phase III results of the RTOG 9508 randomised trial. Lancet 363:1665–1672PubMedCrossRefGoogle Scholar
  16. Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, Schell MC, Werner-Wasik M, Demas W, Ryu J, Bahary JP, Souhami L, Rotman M, Mehta MP, Curran WJ Jr. (2004) Whole brain radiation therapy with or without stereotatic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 363 (9422): 1665–72PubMedCrossRefGoogle Scholar
  17. Angervall I, Wahlquist I (1978) Follow-up and prognosis of renal carcinoma in a series operates by perifascial nephrectomy combined with adrenalectomy and retroperitoneal lymphadenectomy. Eur Urol 4: 13PubMedGoogle Scholar
  18. Aso Y, Homma Y (1992) A survey on incidental renal cell carcinoma in Japan. J Urol 147: 340–343PubMedGoogle Scholar
  19. Assikis VJ, Daliani D, Pagliaro L et al. (2003) Phase II study of an autologous tumor derived heat shock protein-peptide complex vacine (HSPPC-96) for patients with metastatic renal cell carcinoma (mRCC). Prog Am Soc Clin Oncol 22: 286 (Abstr 1552)Google Scholar
  20. Atwell TD, Farrell MA, Callstrom MR, Charboneau JW, Leibovich BC, Patterson DE, Chow GK, Blute ML (2007) Percutaneous cryoablation of 40 solid renal tumors with US guidance and CT monitoring: initial experience. Radiology 243: 267–283CrossRefGoogle Scholar
  21. Atwell TD, Farrell MA, Leibovich BC, Callstrom MR, Chow GK, Blute ML, Charboneau JW (2008) Percutaneous renal cryoblation: experience treating 115 tumors. J Urol 179: 2136–2141PubMedCrossRefGoogle Scholar
  22. Atzpodien J, Buer J, Sel S, Jansen J, Oevermann K (1999) Chemoimmunotherapy in the systemic treatment of advanced renal carcinoma. Urologe A 38(5): 474–478PubMedCrossRefGoogle Scholar
  23. Atzpodien J, Hänninen EL, Kirchner H et al. (1995) Multiinstitutional home-therapy trial of recombinant interleukin-2 and Interferon alfa-2 in progressive metastatic renal cell carcinoma. J Clin Oncol 13 (12): 497–501PubMedGoogle Scholar
  24. Atzpodien J, Kirchner H, Hänninen EL et al. (1999) European studies of interleukin-2 in metastatic renal cell carcinoma. Semin Oncol 20 (Suppl 9): 22–26Google Scholar
  25. Atzpodien J, Kirchner H, Jonas U et al. (2004) Interleukin-2 and interferon alfa-2a-bases immunotherapy in advances renal cell carcinoma: a prospective randomized trial of the German Cooperative renal carcinoma chemoimmunotherapy group. J Clin Oncol 22 (7): 1188–1194PubMedCrossRefGoogle Scholar
  26. Atzpodien J, Körfer A, Franks CR, Pliwoda H, Kirchner H: Home therapy with recombinant interleukin-2 and interferon-alpha-2b in advanced human malignancies. Lancet 1990: 335: 1509–1512PubMedCrossRefGoogle Scholar
  27. Atzpodien J, Royston R, Wandert T, Reitz M and DGCIN — German Cooperative Renal Carcinoma Chemo-Immunotherapy Trials Group (2003) Metastatic renal carcinoma comprehensive prognostic system. B J of Cancer 88: 348–353CrossRefGoogle Scholar
  28. Atzpodien J, Schmitt E, Gertenbach U, Fornara P, Heynemann H, Maskow A, Ecke M, Wöltjen HH, Jentsch H, Wieland W, Wandert T, Reitz M, DGCIN — German Cooperative Carcinoma Chemo-Immunotherapy Trials Group (2005) Adjuvant treatment with interleukin-2 and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN); B J of Cancer 92: 843–946CrossRefGoogle Scholar
  29. Au, KS, Hebert A, Roach ES, Northrup H (1999) Complete inactivation of the TSC2 gene leads to fromation of hamartomas. Am J Hum Genet 65: 1790PubMedCrossRefGoogle Scholar
  30. Aulitzky W, Gastl G, Aulitzky WE et al.: Successful treatment of metastatic renal cell carcinoma with a biologically active dose of IFN-γ. J Clin Oncol 1989; 7: 1875–1884PubMedGoogle Scholar
  31. Baccala A Jr, Hedgepeth R, Kaouk J, Magi-Galluzzi C, Gilligan T, Fergany A (2007) Pathological evidence of necrosis in recurrent renal mass following treatment with sunitinib. Int J Urol 14: 1095–1097PubMedCrossRefGoogle Scholar
  32. Bajorin D, Sell KW, Richard JM et al. (1990) A kine-activated killer cells versus interleukin-2 alone in renal cell carcinoma [abstract 1106]. Proc Am Assoc Cancer Res 31: A1106Google Scholar
  33. Bander NH (1987) Monoclonal antibodies: state of the art. J Urol 137: 603–612PubMedGoogle Scholar
  34. Barama A, St-Louis G, Nicolet V, Hadjeres R, Daloze P (2005) Renal cell carcinoma in kidney allografts: a case series from a single center. Am J Transplant 5(12): 3015–8PubMedCrossRefGoogle Scholar
  35. Becker F, Siemer S, Hack M, Humke U, Ziegler M, Stöckle M (2006) Excellent long-term cancer control with elective nephron-sparing surgery for selected renal cell carcinomas measuring more than 4 cm. Eur Urol 49: 1058–1064PubMedCrossRefGoogle Scholar
  36. Bectol RE, Zagorie RJ (1997) Imaging approach to staging of renal cell carcinoma. Urol Clin North Am 24: 507–522CrossRefGoogle Scholar
  37. Bedke J, Pritsch M, Buse S, Jakobi H; Elsaesser KH, Pahernik S, Haferkamp A, Hofenfellner M (2008) Prognostic Stratification of localized renal cell carcinoma by tumor size. J Urol 180: 62–67PubMedCrossRefGoogle Scholar
  38. Beisland C, Talleraas O, Bakke A, Nordstein J (2006) Multiple primary malignancies in patients with renal cell caricinoma: a national population-based cohort study. BJU Int 698–702Google Scholar
  39. Belldegrun A, Koo AS, Bochner B, Figlin R, de Kernion JB (1990) Immunotherapy for advanced renal cell cancer the role of radical nephrectomy. Eur Urol 18 (2): 42–45PubMedGoogle Scholar
  40. Belldegrun A, Pierce W, Kaboo R et al. (1993) Interferon-alpha primed tumor infiltrating lymphocytes combined with interleukin-2 and interferon-alpha as therapy for metastatic renal cell cardinoma. J Urol 150: 1384–1390PubMedGoogle Scholar
  41. Belldegrun A, Webb DF, Austin III HA, Steinberg SM, Linehans WM, Rosenberg SA (1989) Renal toxicity of interleukin-2 administration in patients with metastatic renal cell cancer: effect of pretherapy nephrectomy. J Urol 141–499–403Google Scholar
  42. Benichou J, Chow W-H, McLaughlin JK, Mandel JS, Fraumeni JF Jr. (1998) Population attributable risk of ranal cell cancer in Minnesota. Am J Epidemiol 14: 424–430Google Scholar
  43. Berdjis N, Hackenberg OW, Zastrow S, Oehlschläger S, Novotny V, Wirth MP (2006) Impact of resection margin status after enphron sparing surgery for renal cell carcinoma. BJU International 97: 1208–1201PubMedCrossRefGoogle Scholar
  44. Berg-Schlosser V (1998) Radiologische Diagnostik maligner Nierentumorer. Dtsch Ärztebl 85: 390–394Google Scholar
  45. Bernsten A, Geertsen PF, Svane IM (2006) Therapeutic dendritic cell vaccination of patients with renal cell carcinomas. Eur Urol 50: 34–43CrossRefGoogle Scholar
  46. Bex A, Blank C, Horenbalst S, Haaren J (2006) Downsizing of unresectable primary metastatic renal cell cancer by sunitinib. A retrospective study. ASOC GU 8: 394Google Scholar
  47. Boorjian SA, Sengupta S, Blute ML (2007) Renal cell carcinoma: vena caval involvement: BJU Int 99: 1239–1244PubMedCrossRefGoogle Scholar
  48. Bjornsson J, Short MP, Kwiatkowski DJ, Henske EP (1996) Tuberous slerosis-associated renal cell carcinoma. Clinical, pathological and genetic features. Am J Pathol 149: 1201PubMedGoogle Scholar
  49. Blom JH, van Poppel H, Marechal JM, Jacqmin D, Sylvester R, Schroder FH, de Prijck L (1999) Radical nephrectomy with and without lymph node dissection: preliminary results of the EORTC randomized phase III protocol 30881. EORTC Genitourinary Group. Eur Urol 36: 570–575PubMedCrossRefGoogle Scholar
  50. Bloom DA, Kaufmann JJ, Smith RB (1981) Late recurrence of renal tubular carcinoma. J Urol 126: 546–648PubMedGoogle Scholar
  51. Blute ML, Leibovich BC, Lohse CM, Cheville JC, Zincke H (2004) The Mayo Clinic experience with surgical management, complications and outcome for patients with renal cell carcinoma and venous tumour thrombus. BJU International 94: 33–41PubMedCrossRefGoogle Scholar
  52. Bodmer et al. (2002) Understanding familial and non-familial renal cell cancer. Hum Mol Genet 11:2489–2498PubMedCrossRefGoogle Scholar
  53. Brausi MA, Gavioli M, de Luca G, Verrini G, Peracchia GC, Simonini GL, Viola M (2007) Retroperitoneal lymph node dissection (RPLD) in conjunction with nephroureterectomy in the treatment of infiltrativi transitional cell carcinoma (TCG) of the upper urinary tract: Impact of Survival. Eur Urol 52: 1414–1420PubMedCrossRefGoogle Scholar
  54. Brenner H, Stegmaier C, Ziegler H (2005) Long-term survival of cancer patients in Germany achieved by the beginning of the third millennium. Ann Oncol 16 (6): 981–6PubMedCrossRefGoogle Scholar
  55. Bretan PN, Busch MP, Hricak H (1986) Development of a acquired renal cysts and renal cell carcinoma. Cancer 57: 1871–1879PubMedCrossRefGoogle Scholar
  56. Brinkmann OA, Bruns F, Gosheger G, Micke O, Hertle L (2005) Treatment of bone metasases and local recurrence from renal cell carcinoma with immunochemotherapy and radiation. World J Urol 23 (3): 185–90PubMedCrossRefGoogle Scholar
  57. Brkovic D, Riedasch G, Waldherr R, Röhl I, Staehler G (1994) Lokale Rezidive nach orgenerhaltender Nierentumorchirurgie. Urologe A 33: 104–109PubMedGoogle Scholar
  58. Brunelli M, Eble JM, Zhang S, Martignoni G, Delahunt B, Cheng L (2004) Eosinophilic and classis chromophobe renal cell carcinomas have similar freqeunt losses of multiple chromosomes from among chromosomes 1, 2, 6, 10 and 17, and this pattern of genetic abnormality is not present in renal oncocytoma. Mod. Pathol 18: 161–169CrossRefGoogle Scholar
  59. Bruno JJ, Snyder ME, Motzer RJ, Russo P (2006) Renal cell carcinoma local recurrences: impact of surgical treatment and concomitant metastases on survival. BJU International 97: 933–938PubMedCrossRefGoogle Scholar
  60. Bruntsch U, Heinrich B, Kaye SB et al. (1994) Docetaxel (Taxotere) in advanced renal cell cancer. A phase II trial of the EORTC Early Clinical Trials Group. Eur J Cancer 30A: 1067–1067Google Scholar
  61. Bülow H, Sebeikat D, Demetriou D (1991) Ist die Adrenalektomie bei der Tumornephrektomie immer erforderlich? Urologe A 30: 341–343PubMedGoogle Scholar
  62. Campbell SC, Novick AC, Herts B, Fischler DF, Meyer J, Levin HS et al. (1997) Prospective evaluation of fine needle aspiration on small, solid renal masses: accuracy and morbidity. Urology 50: 25PubMedCrossRefGoogle Scholar
  63. Canfield SE, Kamat AM, Sanchez-Ortiz RF, Detry M, Swanson DA, Wood CG (2006) Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease (clinical stage T×N1-2M0): the impact of aggressive surgical resection on patient outcome. J Urol 175 (3 Pt2): 864–9PubMedCrossRefGoogle Scholar
  64. Carini M, Seli C, Barbanti G, Iapini A, Turini D, Costatini A (1988) Sonservative surgical treatment of renal cell carcinoma: clinical experience and reappraisal of indications. J Urol 140: 725–731PubMedGoogle Scholar
  65. Carl P, Klein U, Gebauer A, Schmiedt E (1977) The value of lymphography for the TNM classification of renal carcinoma. Eur Urol 3: 286–288PubMedGoogle Scholar
  66. Castilla EA, Liou LS, Abrahams NA (2002) Prognostic importance of resection margin after nephron-sparing surgery for reanl cell carcinoma. Urology 60: 993–997PubMedCrossRefGoogle Scholar
  67. Cestari A, Guazzoni G, Dell’Acqua V, Nava L, Gardone G, Balconi G, Naspro R, Montorsi F, Rigatti P (2004) Laparoskopic cryoablation of solid renal masses: intermediate term followup. J Urol 173: 1267–1270CrossRefGoogle Scholar
  68. Chang AE, Li Q, Jiang G, Sayre DM, Braun TM, Redman BG (2003) Phase II trial of autologous tumor vaccination, anti-CD3-activated vaccine-primed lymphocytes, and interleukin-2 in stage IV renal cell cancer. J Clin Oncol 21 (5): 884–890PubMedCrossRefGoogle Scholar
  69. Chawla SN, Crispen PL, Hanlon AL, Greenberg RE, Cheng DYT, Uzzo rG (2006) The natural history of observed enhancing renal masses: meta analysis and review of the world literature. J Urol 175: 425–431PubMedCrossRefGoogle Scholar
  70. Chen F, Kishida T, Yao M, Hustad T, Glavac D, Dean M, Gnarra JR, Orcutt ML, Duh FM, Glenn G, Green J, Hsia YE, Lamiell J, Li H, Wei MH, Schmidt L, Tory K, Luzmin I, Stackhouse T, Latif F, Linehan WM, Lerman M, Zbar B (1995) Germline mutations in the Von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype. Human Mutation 5: 66–75PubMedCrossRefGoogle Scholar
  71. Chen WS, Farrow GM, Zincke H (1991) The incidence of multientricity in renal cell carcinoma. J Urol 146: 1221–1223Google Scholar
  72. Choueiri TK, Garcia JA, Elson P, et al. (2007) Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer 110: 543–550PubMedCrossRefGoogle Scholar
  73. Choueiri TK, Baz RC, McFadden CM, Khasawneh M, Karam MA, Kelly M, Hussein MA (2008) An association between renal cell carcinoma and multiple myeloma: a case series and clinical implication. BJU Int 101(6) 712–715PubMedCrossRefGoogle Scholar
  74. Choueiri TK, Plantade A, Elson P, Negrier S et al. (2008) Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol 126: 127–131CrossRefGoogle Scholar
  75. Chow WH, Devesa SS, Warren JL, Fraumeni JF (1999) Rising Incidence of renal cell cancer in the United States. Jama 281: 1628–31PubMedCrossRefGoogle Scholar
  76. Chu TM, Rupnick MA, Kerkela R, et al. (2007) Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 370:2011–2019PubMedCrossRefGoogle Scholar
  77. Choyke PL, Glenn G, Walther MM et al. (2003) Hereditary renal cancers. Radiology 22: 33–46CrossRefGoogle Scholar
  78. Cindolo L, Patard JJ, Chiodini P, Schips L, Ficarra V, Tostain J, de La Taille A, Altieri V, Lobel B, Zigeuner RE, Artibani W, Guillé F, Abbou CC, Salzano L, Gallo C (2005) Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy: a multicenter European study. Cancer 104: 1362–71PubMedCrossRefGoogle Scholar
  79. Clark JI, Atkins MB, Urba WJ, Creech S, Figlin RA, Dutcher JP, Flaherty L, Sosman JA, Logan TF, White R, Weiss GR, Redman BG, Tretter CPG, McDermott D, Smith JW, gordon MS, Margolin KA (2003) Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trail. J Clin Oncol 21 (6): 3133–3140PubMedCrossRefGoogle Scholar
  80. Cohen AJ, Frederick P, Berg S, Marchetto DJ, Tsai S, Jacobs SC, Brown RS (1979a) Hereditary renal-cell carcinoma associated with a chromosomal translocation. N Engl J Med 13: 592–5Google Scholar
  81. Cohen AJ, Li FP, Berg S et al. (1979b) Hereditary renal cell carcinoma ssociated with a chromosome translocation. N Engl J Med 301: 592PubMedGoogle Scholar
  82. Cohen D, Zhou M (2005) Molecular genetics of familial renal cell carcinoma syndromes. Clin Lab Med 25 (2): 259–77PubMedCrossRefGoogle Scholar
  83. Cooper CS, Cohen MB, Donovan JF (1996) Splenectomy complicating left nephrectomy. J Urol 155: 30–36PubMedCrossRefGoogle Scholar
  84. Coppin C, Porzsolt F, Awa A, Kumpf J, Goldman A, Wilt T (2004) Immunotherapy for advances renal cell cancer. Cochrane Database System Rev 3: CD001425Google Scholar
  85. Corman JM, Penson DF, Hur K, Khuri SF, Daley J, Henderson W, Krieger JN (2001) Comparison of complications after radical and partial nephectomy: results from the National Veterns Administration Surgical Quality Improvement Program. BJU Int 88 (1): 126Google Scholar
  86. Crispen PL, Uzzo RG (2007) The natural history of untreated renal masses. BJU Int 99: 1203–1207PubMedCrossRefGoogle Scholar
  87. Czenne K, Hemminki K (2003) Familial papillary renal cell tumors and subsequent cancers: a nationwide epidemiological study from Sweden. J Urol 169: 1271–1275CrossRefGoogle Scholar
  88. Dall’Oglio MF, Antunes AA, Sarkis AS, Crippa A, Leite KR, Lucon AM, Srougi M (2007) Microvascular tumour invasion in renal cell carcinoma: the most important prognostic factor. BJU Int 100: 552–555PubMedCrossRefGoogle Scholar
  89. Dalla-Palma L, Pozzi-Mucelli F, di Donna A, Pozzi-Mucelli RS (1990) Cystic renal tumors: US and CT findings. Urol Radiol 12: 67–73PubMedCrossRefGoogle Scholar
  90. Dannull J, Su Z, Rizzieri D, Yang BK, Coleman D, Yancey D, Zhang A, Dahm P, Chao N, Gilboa E, Vieweg J (2005) Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 115 (12): 3623–33PubMedCrossRefGoogle Scholar
  91. Dash A, Vickers AJ, Schachter LR Bach AM, Snyder ME, Russo P (2006) Comparison oft outcomes in elective partial vs radical nephrectomy for clear cell renal cell carcinoma of 4–7cm. BJU International 97: 939–945PubMedCrossRefGoogle Scholar
  92. De Baere T, Risse O, Kuoch V et al. (2003) Adverse events during radiofrequency treatment of 582 hepativ tumors. AJR Am J Roentgenol 181: 695–700PubMedGoogle Scholar
  93. De Forges A, Rey A, Klink M, Ghosn M, Kramar A, Droz JP (1988) Prognostic factors of adult metastatic renal carcinoma: a multivariate analysis. Semin Surg Oncol 4 (3): 149–154PubMedCrossRefGoogle Scholar
  94. De Mulder PH. Weissbach L, Jakse G, Osieka R, Blatter J (1996) Gemcitabine: a phase II study in patients iwht advanced renal cancer. Cancer Chemother Pharmacol 37: 491–495PubMedCrossRefGoogle Scholar
  95. Dechet CB, Zincke H, Sebo TJ, King BF, LeRay AJ, Farrow GM et al. (2003) Prospective analysis of computerized tomography and needles biopsy with permanent sectioning to determine the nature of solid renal masses in adults. J Urol 169: 71PubMedCrossRefGoogle Scholar
  96. DeKernion JB, Berry D (1980) The diagnosis and treatment of renal cell carcinoma. Cancer 45: 1947–56PubMedGoogle Scholar
  97. DeKernion JB, Huland H (1990) The operable renal cell carcinoma: Summary and conclusions. Eur Urol 2: 48–51Google Scholar
  98. DeKernion JB, Ramming KP, Smith RB (1978) The natural history of metastatic renal cell carcinoma. a computer analysis. J Urol 120: 148–152PubMedGoogle Scholar
  99. Desai MM, Strzempkowski B, Matin SF, Steinberg AP, Ng C, Meraney Am et al. (2005) Prospective randomized comparison of transperitoneal versus retrioperitoneal laparoscopic radical nephrectomy. J Urol 173: 38–41PubMedCrossRefGoogle Scholar
  100. Dexeus FH, Logothetics CJ, Sella A et al. (1991) Circadian infusion of floxuridin in patients with metastatic renal cell carcinoma. J Urol 146: 709–713PubMedGoogle Scholar
  101. Dillenburg W, Dillenburg W, Poulakis V, Skriapas K, de Vries R, Ferakis N, Witzsch U, Melekos M, Becht E (2006) Retroperitoneoscopic versus open surgical radical nephrectomy for large renal cell carcinoma in clinical stage cT2 or cT3a: quality of life, pain and reconvalescence. Eur Urol 49: 314–323PubMedCrossRefGoogle Scholar
  102. Diller R, Gruber A, Wolters H, Senninger N, Spiegel HU (2005) Therapy and prognosis of tumors of the genitorurinary tract after kidney transplantation. Transplant Proc 37 (5): 2089–92PubMedCrossRefGoogle Scholar
  103. Dineen MK, Pastore RD, Emrich IJ, Huben RP (1988) Results of surgical treatment of renal cell carcinoma with solitary metastasis. Urol 140: 277–279Google Scholar
  104. Di Silverio F, Sciarra A, Parente U, Andrea A, von Heland M, Panebianco V, Passariello R (2008) Neoadjuvant therapy with sorafenib in advanced renal cell carcinoma with vena cava extension submitted to radical nephrectomy. Urol Int 80: 451–453PubMedCrossRefGoogle Scholar
  105. Drachenberg D, Childs RW (2003) Allogeneic hematopoetic stem cell transplantation for cytokine refractory renal cell carcinoma. Cancer Treat Res 116: 213–226PubMedGoogle Scholar
  106. Dranoff G et al. (1983) Vaccination with irradiated tumor engineered to secrete murine granulozyte-macorphage colony-stimulating factor simulated protent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 90 (8): 339Google Scholar
  107. Dunn J (2000) Laparoscopic versus open radical nephrectomy: a 9-year experience. Urol 164: 1153–1159CrossRefGoogle Scholar
  108. Durr HR, Maier M, Pfahler M, Baur A, Refior HJ (1999) Surgical treatment of osseous metastases in patients with renal cell carcinoma. Clin Orthop 367: 283–290PubMedGoogle Scholar
  109. Dutcher JP, Szczylik C, Tannir N et al. (2007) Correlation of survival with tumor hisotlogy, age, and prognostic risk group for previously untreated patients with advandes renal cell carcinoma (adv RCC) receiving temsirolimus (TEMSR) or interferon-alpha (IFN). Proc Am Soc Clin Oncol J Clin Oncol 25: 5033Google Scholar
  110. Ebert T, Schnell D, Weissbach L (2005) Lymph node dissection in patients with renal cell carcinoma Urologe A 44 (6): 635–7PubMedCrossRefGoogle Scholar
  111. Eggener SE, Yossepowitch O, Pettus JA, Snyder ME, Motzer RJ, Russo P (2006) Renal cell carcinoma recurrence after nephrectomy for localized disease: predicting survival from time of recurrence. J Clin Oncol 24: 3101–3106PubMedCrossRefGoogle Scholar
  112. Elson PJ, Witte RS, Trump DI (1988) Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res 48: 7310–7313PubMedGoogle Scholar
  113. Eschenbach AC von, Avallone A, Price J, Swanson D, Killion J, Stephenson R, Fidler IJ (1990) The biology of renal cancer the influence of nephrectomy. Eur Urol 18 (2): 40–41Google Scholar
  114. Escudier B, Choueiri TK, Oudard S, Szczylik C, Negrier S, Ravaud A, Chevreau C, Vener P, Champagne P, Croteau D, Dupont E, Hariton C, Bukowski RM (2007) Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: new paradigm from a large phase III trial with shark cartilage extract. AE 941. J Urol 178: 1901–1905PubMedCrossRefGoogle Scholar
  115. Escudier B, Pluzanska A, Koralewski P et al. (2007) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370: 2103–2111PubMedCrossRefGoogle Scholar
  116. Fakhrai N, Haitel A, Balassy C, Zielinski CC, Schmidinger M (2005) Major response and clinical benefit following third-line treatment for Bellini duct carcinoma. Wien Klin Wochenschr 117: 63–65PubMedCrossRefGoogle Scholar
  117. Falchrai H, Shawlet DI, Gjerset R, Naviaux RK, Koziol J, Royston I, Sobol RE (1995) Cytokine gene therapy with interleukin-2 transduced fibroblasts: Effect ofIL-2 dose on anti-tumor immunity. Hum Gene Ther 6: 591–601CrossRefGoogle Scholar
  118. Fein AB, Lee JKT, Balte DM et al. (1987) Diagnosis and staging of renal cell carcinoma: a comparison of MR imaging and CT. Am J Roentgenol 148 (4): 749–753Google Scholar
  119. Fergany AF, Hafez KS, Novick AC (2000) Long-term results of nephron sparing surgery for localized renal cell carcinoma: 10-year followup. J Urol 163 (2): 442–5PubMedCrossRefGoogle Scholar
  120. Fergany AF, Saad IR, Woo L, Novick AC (2006) Open partial nephrectomy for tumor in a solitary kidney: expereince with 400 cases. J Urol 175: 1630–1633PubMedCrossRefGoogle Scholar
  121. Ficarra V, Martignoni, G, Lohse C, Novara G, Pea M, Cavalleri S, Artibani W (2006) External validation of the Mayo Clinic Stage. Size, Grade and Necrosis (SSIGN) score to predict cancer-specific survival using a European series of conventional renal cell carcinoma. J Urol 175: 1235–1239PubMedCrossRefGoogle Scholar
  122. Ficarra V, Galfano A, Mancini M et al. (2006) Reassesing the current TNM lymph node staging for renal cell carcinoma. Eur Urol 49: 324–331CrossRefGoogle Scholar
  123. Ficarra V, Novara G (2008) The new medical treatment of metastatic renal cell carcinoma: A good debut, a lot of open questions. Eur Urol 54:252–255PubMedCrossRefGoogle Scholar
  124. Figlin RA, Pierce WC, Kaboo R, Tso CL, Moldawer N, Gitlitz B, deKernion J, Belldegrun A (1997) Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8(+) selected tumor infiltrating lymphocytes from primary tumor. J Urol 158: 740–745PubMedCrossRefGoogle Scholar
  125. Filipas D, Spix C, Schulz-Lampel D, Michaelis J, Hohenfellner R, Roth S, Thuroff JW (2003) Screening for renal cell carcinoma using ultrasonography: a feasibility study. BJU Int 91: 595–9PubMedCrossRefGoogle Scholar
  126. Finley DS, Beck S, Box G, Chu W, Deane L, Vajgrt DJ, McDougall EM, Clayman RV (2008) Percutaneous and laparoscopic cryoablation of small renal masses. J Urol 180: 492–498PubMedCrossRefGoogle Scholar
  127. Fischer CG, Wächter W, Fuenctecilla PE, Miller J, Weidner W, Dudeck J (1997) Urologische Tumore in Deutschland. Urologe A 36: 143–150PubMedCrossRefGoogle Scholar
  128. Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, Caton JR Jr, Munshi N, Crawford ED (2001) Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 345: 1655–9PubMedCrossRefGoogle Scholar
  129. Flanigan RC, Yonover PM (2001) The role of resection for patients with renal carcinoma. Curr Oncol Rep 3: 424–32PubMedCrossRefGoogle Scholar
  130. Fleischmann JD, Kim B (1991) Interleukin-2 immunotherapy followed by resection of residual renal cell carcinoma. J Urol 145: 938–41PubMedGoogle Scholar
  131. Flocks RH, Kadesky MC (1958) Malignant neoplasmas of the kidney: an analysis of 353 patients followed 5 years or more. J Urol 79: 196PubMedGoogle Scholar
  132. Fossa SD (2000) Interferon in metastatic renal cell carcinoma. Semin Oncol 27 (2): 187–193PubMedGoogle Scholar
  133. Forges et al. (1988) Prognostic factors of adult metastatic renal carcinoma: a multivariate analysis. Semin Surg Oncol 4:149–154PubMedCrossRefGoogle Scholar
  134. Fourquier P, Regnard JF, Rea S, Levi JF, Levasseur P (1997) Lung metastases of renal cell carcinoma: results of surgical resection. Eur J Cardiothorac Surg 11: 17–21PubMedCrossRefGoogle Scholar
  135. Fowler JE Jr (1986) Failure of immunotherapy for metastatic renal cell carcinoma. J Urol 135: 22–25PubMedGoogle Scholar
  136. Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H (2003) Solid renal tumors: an analysis of pathological features relates to tumor size. J Urol 170: 2217–2220PubMedCrossRefGoogle Scholar
  137. Frank I, Colombo JR, Rubinstein M, Desai M, Kaouk J, Indesbir S (2006) Laparoscopic partial nephrectomy for centrally located renal tumors: Frank I, Colombo JR, Rubinstein M, Desai M, Kaouk J, IS Gill. J Urol 175: 849–852PubMedCrossRefGoogle Scholar
  138. Freed SZ, Halperin JP, Gordon M (1977) Idiopathic regression of metastases from renal cell carcinoma. J Urol 118: 538–42PubMedGoogle Scholar
  139. Fuzesi L, Gunawan B, Braun S et al. (1994) Renal oncocytoma with a translocation t (9; 11) (p23; q13). J Urol 152: 471–472PubMedGoogle Scholar
  140. Fyfe GA, Fisher RI, Rosenberg SA et al. (1996) Long-term response data for 255 atients with metastatic renal cell carcinoma treated with high-does recombinant interleukin-2 therapy. J Clin Oncol 14: 2410–2411PubMedGoogle Scholar
  141. Galfano A, Novara G, Iafrage M, Cavalleri S, Martignoni G, Gardiman M, D’Elia C, Patard JJ, Artibani, W, Ficarra V (2008) Mathematical models for prognostic prediction in patients with renal cell carcinoma. Urol Int 80: 113–123PubMedCrossRefGoogle Scholar
  142. Gansbacher B (1992) A Pilot study of immunization with IL-2 secreting allogeneic HIA-A2 matched renal cell carcinoma cells in patients with advances renal cell carcinoma. Hum Gene Ther 3 (6): 691–703CrossRefGoogle Scholar
  143. Gastl G, Finstad CL, Guarini A, Bosl G, Gilboa E, Bander NH, Gansbacher B et al. (1992) Retroviral vector-mediated lymphokine gene transfer into human renal cancer cells. Cancer Res 52 (22): 6229–6236PubMedGoogle Scholar
  144. George CM, Volgelzang NJ, Rini BI, Geofffroy FJ, Kollipara P, Stadler WM (2002) A phase II trial of weekly intravenous gemcitabine and cisplatin with continuous infusion fluorouracil in patients with metastatic renal cell carcinoma. Ann Oncol 13: 116–120PubMedCrossRefGoogle Scholar
  145. Gervais DA, Arellano RS, McGovern FJ, McDougal WS, Mueller PR (2005a) Radiofrequency ablation of renal cell carcinoma: part 2, lessons learned with ablation of 100 tumors. AJR 185: 72–80PubMedGoogle Scholar
  146. Gervais DA, Arellano RS, Mueller PR (2005b) Percutaneous radiofrequency ablation of renal cell carcinoma. Eur Radol 15: 960–967CrossRefGoogle Scholar
  147. Gervais DA, McGovern FJ, Arellano RS, McDougal WS, Mueller PR (2005) Radiofrequency ablation of renal cell carcinoma: Part I, Indications, Results, and Role in Patient Managemtn over a 6-Year Period and Ablation of 100 Tumors. AJR 185: 64–71PubMedGoogle Scholar
  148. Ghavamian R, Cheville JC, Lohse CM, Weaver AL, Zincke H, Blute ML (2002) Renal cell carcinoma in the solitary kidney: an analysis of complications and outcome after nephron sparing surgery. J Urol 168 (2): 454–9PubMedCrossRefGoogle Scholar
  149. Gill IS, Martin SF, Desai MM, Kaouk JH, Steinberg A, Mascha E, Thornton J, Sherief MH, Strzempkowski B, Novick AC (2003) Comparative analysis of laparoscopic versus open partial nephrectomy for renal tumors in 200 patients. J Urol 170 (1): 64–8PubMedCrossRefGoogle Scholar
  150. Gill IS, McClennan BL, Kerbl K, Carbone JM, Wick M, Clayman RV (1994) Adrenal involvement from renal cell carcinoma: predictive value of computerized tomography: J Urol 152: 1082–1085PubMedGoogle Scholar
  151. Gill IS, Remer EM, Hasan WA, Strzempkowski B, Spaliviero M, Steinberg AP, Kaouk JH, Desai MM, Novick AC (2005) Renal cryoablation: outcome at 3 years. J Urol 173: 1903–1907PubMedCrossRefGoogle Scholar
  152. Gill, IS, Kavoussi LR, Lane BR, Blute ML, Babineau D, Colombo Jr. JR, Frank I, Permpongkosol S, Weight CJ, Kaouk JH, Kattan W, Novick AC (2007) Comparison of 1,800 laparoscopic and open partial nephrectomy for single renal tumors. J Urol 178: 41–46PubMedCrossRefGoogle Scholar
  153. Gimenez-Bachs JM, Salinas-Sanchez AS, Sanchez-Sanchez F, Lorenzo-Romero JG, Donate-Moreno MJ, Pastor-Navarro H, Garcia-Olmo DC, Escribano-Martinez J, Virseda-Rodriguez JA (2006) Determination of vhl Gene Mutations in Sporadic Renal Cell Carcinoma. Eur Urol 49: 1051–1057PubMedCrossRefGoogle Scholar
  154. Giuliani I, Giberti C, Martorane G, Rovida S (1990) Radical estensive surgery for renal cell carcinoma: long-term results and prognostic factors. J Urol 143: 468–474PubMedGoogle Scholar
  155. Glassberg KI (2002) Renal dysplasis and cystic disease of the kidney. In: Campbell’s Urology. 8. edn. Elsevier Science, pp 1443–1495Google Scholar
  156. Gleave ME, Elhilali M, Fradet Y et al. and the Canadian Urologic Oncology Group (1998) Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. N Engl J Med 338: 1265–1271PubMedCrossRefGoogle Scholar
  157. Glenn GM, Linehan WM, Hosoe S et al. (1992) Screening for von Hippel-Lindau disease by DNA-polymorphism analysis. JAMA 267: 1226–31PubMedCrossRefGoogle Scholar
  158. Gnarra J, Tory K, Weng Y, Schmidt L, Wei MH, Li H, Latif F, Liu S, Chen F, Duh FM, Lubensky I, Duan DR, Florecne C, Pozzatti R, Walther MM, Bander NH, Grossmann HB, Brauch H, Pomer S, Brooks JD, Isaacs WB, Lermann MI, Zbar B, Linehan WM (1994) Mutations of the VHL tumor suppressor gene in renal carcinoma. Natur Genetics 7: 85–90CrossRefGoogle Scholar
  159. Gnarra JR, Tory K, Weng Y et al. (1994) Mutations fo the von Hippel-Lindau tumor suppressor gene in renal carcinoma. Nat Genet 7: 85PubMedCrossRefGoogle Scholar
  160. Goepel M, Rübben H (1991) Adjuvant herapy in renal cancer. Word J Urol 9: 232–236Google Scholar
  161. Goering JD, Mahvi DM, Niederhuber JE, Chicks D, Rikkers LF (2002) Cryoablation and liver resection for noncolorectal liver metastases. Am J Surg 183: 384–389PubMedCrossRefGoogle Scholar
  162. Gogus C, Baltaci S, Beduk Y, Sahinli S, Kupeli S, Gogus O (2003) Isolated local recurrence of renal cell carcinoma after radical nephrectomy: experience with 10 cases. Urology 61: 926–9PubMedCrossRefGoogle Scholar
  163. Goldfarb DA, Novk AC, Lorig R et al. (1990) Magnetic resonance imaging for assessment of vena caval tumor thrombi: a comparative study with venocavography and computerized tomography scanning. J Urol 144: 110–1104Google Scholar
  164. Golimbu M, AIAskari S, Tessler A, Morale P (1994) Aggressive treatment of metastatic renal cancer. J Urol 136: 805–807Google Scholar
  165. Golumbek PI et al. (1991) Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 254 (5032): 713–716PubMedCrossRefGoogle Scholar
  166. Gofrit ON, Shapiro A, Pizov G, Landau EH, Katz R, Zorn KC, Pode D (2007) Does stage T3a renal cell carcinoma embrace a homogeneous group of patients? J Urol 177: 1682–1686PubMedCrossRefGoogle Scholar
  167. Golshayan AR, George S, Heng DY, Elson P, Wood LS, Mekhail TM, Garcia JA, Aydin H, Zhou M, Bukowski RM, Rini BI (2009) Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. J Clin Oncol 27: 235–41PubMedCrossRefGoogle Scholar
  168. Gorge DG, Michaelson MD, Rosenberg JE, et al. (2007) Phase II trial of sunitinib in bevacizumab-refractory metastatic renal cell carcinoms (mRCC). Proc Am Soc Clin Oncol J Clin Oncol 25: 5035Google Scholar
  169. Grigon DJ, Ayala AG, EINaggar A et al. (1989) Renal cell carcinoma — a clinico pathologic and DNA flow cytometric analysis of 103 cases. Cancer 64: 2133–2140CrossRefGoogle Scholar
  170. Grossmann HB, Sommerfeld D, Konnak JW, Bromberg J (1994) Long-term assessment of renal function following nephrectomy for state I renal carcinoma. Br Urol 74: 279–282CrossRefGoogle Scholar
  171. Gupta A, Allaf ME, Kavoussi LR, Jarrett TW, Chan DYS, Su LM, Solomon SB (2006) Cumputerized tomography gruides percutaneous renal cryoablation with the patient under conscious sedation: initial clinical experience. J Urol 175: 447–453PubMedCrossRefGoogle Scholar
  172. Hafez KS, Fergary AF, Novick AC (1999) Nephron sparing surgery for localized renal cell carcinoma: impact of tumor size on patient survival, tumor recurrence and TNM staging. J Urol 162 (6): 1930–1933PubMedCrossRefGoogle Scholar
  173. Hansel DE (2006) Genetic alterations and histopathologic findings in familial renal cell carcinoma. Histol Histopathol 21 (4): 437–44PubMedGoogle Scholar
  174. Hatcher PA, Anderson EE, Pauson DF et al. (1991) Surgical management and prognosis of renal cell carcinoma invading the vana cava. J Urol 145: 20–24PubMedGoogle Scholar
  175. Hellsten S, Johnsen J, Berge T, Linell F (1990) Clinically unrecognized renal cell carcinoma. Eur Urol 18 (2): 2–3PubMedGoogle Scholar
  176. Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, Liu S, Samid D, Duan DSR, Gnarra JR, Linehan WM, Baylin SB (1994) Silencing of the VHL tumor-supressor gene by DNA methylation in renal carcinoma. Genetics 91: 9700–04Google Scholar
  177. Hermanek P, Schrott KM (1990) Evaluation of the new tumor, nodes and metastases classification of renal cell carcinoma. J Urol 144: 238–242PubMedGoogle Scholar
  178. Hernberg M, Virkkunen P, Bono P, Ahtinen H, Maenpaa H, Joensuu H (2003) Interferon alfa-2b three times daily and thalidomide in the treatment of metatatic renal cell carcinomas. J Clin Oncol 21 (20): 3770–3776PubMedCrossRefGoogle Scholar
  179. Herring JC, Enqust EG, Chernoff A et al. (2001) Parenchymal sparing surgery in patients with hereditary renal cell carcinoma: 10-year experience. J Urol 165: 777–781PubMedCrossRefGoogle Scholar
  180. Herrlinger A, Schrott KM, Schott G, Sigel A (1991) What are the benefits of extendes dissection of the regional lymph nodes in the therapy of renal cell carcinoma? J Urol 146: 1224–1227PubMedGoogle Scholar
  181. Hino O, Kobayashi T, Okimoto K (2006) Genetic and environmental factors in hereditary predisposition to tumors: a conceptual overview. EXS 96: 269–92PubMedGoogle Scholar
  182. Hitt E (2003) Low-dose thalidomide adds minimal benefit to patients with renal cell carcinoma taking interferon. J Clin Oncol 21 (20): 370–3776Google Scholar
  183. Hock LM, Lynch J, Balaji KC (2002) Increasing incidence of all stages of kidney cancer in the last 2 decades in the Unites States: an analysis of surveillance, epidemiology and end results program data. J Urol 167: 57–60PubMedCrossRefGoogle Scholar
  184. Hofmockel G, Langer W, Theiss M, Gruss A, Frohmuller HG (1996) Immunochemotherapy for metastatic renal cell carcinoma using a regimen of interleukin-2, interferon-α and 5-fluorouracil. J Urol 156 (1): 18–21PubMedCrossRefGoogle Scholar
  185. Höltl L, Zelle-Rieser C, Gander H, Papesh Ch, Ramoner R, Bartsch G, Rogatsch H, Barsoum AD, Coggin JH, Turnher M (2002) Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dentritic cells. Clin Cancer Res 8: 3369–3376PubMedGoogle Scholar
  186. Horoszewicz JS, Murphy GP (1989) An assessment of the current use of human interferons in therapy of of urological cancers. J Urol 142: 173–1179Google Scholar
  187. Hovsepian DM, Leva H, Amis ES Jr, Newhouse JH (1990) MR evaluation of renal space-occupving lesions: diagnostic criteria. Urol Radiol 12: 74–79PubMedCrossRefGoogle Scholar
  188. Hrushesky WJ, Von Roemeling R, Fraley EE, Rabatin JT (1988) Circadian-based infusional chrono-chemotherapy controls progressive metastatic renal cell carcinoma. Semin Surg Oncol 4: 110–115PubMedGoogle Scholar
  189. Huang WC, Levey AS, Serio AM, et al. (2006) Chronic kidney disease after nehrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol 7: 735–740PubMedCrossRefGoogle Scholar
  190. Hunt JD, van der Hel OL, McMillan GP, Boffetta P, Brennan P (2005) Renal cell carcinoma in relation to cigarette smoking: meta-analysis of 24 studies. Int J Cancer 114: 101–118PubMedCrossRefGoogle Scholar
  191. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, O’Toole T, Kong S, Moore L (2006) A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk pathets with advanced renal cell carcinoma (advRCC). J Clin Oncol 24 (Abstr. LBA4)Google Scholar
  192. Huland E, Heinzer H, Mir TS, Huland H (1997) Inhales interleukin-2 in pulm, onary metastic renal-cell carcinoma: 6 years of expeience. Cancer J Sci Am 3: 98–105Google Scholar
  193. Huland E, Huland H, Heinzer H (1992) Interleukin-2 by inhalation: local therapy for metastatic renal-cell carcinoma. J Urol 147: 344–348PubMedGoogle Scholar
  194. Hulten I, Rosencrantz M, Seeman I, Wahlquist I, Ahren C (1969) Occurrence and localization of lymph node metastases in renal cell carcinoma. A lymphographic and histopathological investigation in connection with nephrectomy. Scand I Urol Nephrol 3: 129CrossRefGoogle Scholar
  195. Hutson TE (2008) Renal cell carcinoma: what does the future hold? BJU Int 102: 5–8PubMedCrossRefGoogle Scholar
  196. Iliopoulos O, Kibel A, Gray S, Laelin WG Jr. (1995) Tumor suppression by the human von Hippel-Lindau gene product. Natur Medicine 1(8): 822–6CrossRefGoogle Scholar
  197. Imamoglu MA, Bakirta H, Sagnak L, Tuygun C, Ersoy H (2002) A comparison of two different incisional approaches in the surgical treatment of renal cell carcinoma. Int Urol Nephrol 33(1): 7–11PubMedCrossRefGoogle Scholar
  198. Ishikawa I, Ishii H, Shinoda A, Tateishi K, Ben A, Suzuki K, Tsugawa R (1991) Renal cell carcinoma of the native Kidney after renal transplantation, a case report and review of the literature. Nephron 58: 354–358PubMedCrossRefGoogle Scholar
  199. Ishikawa I, Saito Yasuhito, Shikura N, Kitada H, Shinoda A, Suzuki S (1990) Ten-year prospective study on the development of renal cell carcinoma in dialysis patients. Am J Kidney Dis 5: 452–458Google Scholar
  200. Itano NB, Blute ML, Spotts B, Zincke H (2000) Outcome of isolated renal cell carcinoma fossa recurrence after nephrectomy. J Urol 164: 322–5PubMedCrossRefGoogle Scholar
  201. Jakse G (1989) Operative Technik beim Nierentumor mit Cavathrombus. Aktuel Urol 20: V–XCrossRefGoogle Scholar
  202. Janetschke G, Jeschke K, Peschel R, Strohmeyer D, Henning K, Bartsch G (2000) Laparoscopic surgery for T1 renal cell carcinoma. Eur Urol 38: 131–138CrossRefGoogle Scholar
  203. Jarret TW, Sweetser PM, Weiss GH, Smith AD (1995) Percutaneous management of transitional cell carcinoma of the renal collecting system: 9-year experience. J Urol 154: 1629–1635CrossRefGoogle Scholar
  204. Jayson M, Sanders H (1998) Increased incidence of serendipitously discovered renal cell carcinoma. Urology 51: 203–205PubMedCrossRefGoogle Scholar
  205. Jeong IG, Jeong CW, Hong SK, Kwak C, Lee E, Lee SE (2006) Prognostic implication of capsular invasion without perinephric fat infiltration in localized renal cell carcinoma. Urology. 67: 709–712PubMedCrossRefGoogle Scholar
  206. Jermann M, Stahel RA, Salzberg M et al. (2006) A phase II, open-label study of gefitinib (IRESSA) in patients with locally advance, metastatic, or relapsed renal-cell carcinoma. Cancer Chemother Pharmacol 57 (4): 533–539PubMedCrossRefGoogle Scholar
  207. Jeschke K, Peschel R, Wakonig J, Schellander L, Bartsch G, Henning K (2001) Laparoscopic nephron-sparing surgery for renal tumors. Urology 58: 688–692PubMedCrossRefGoogle Scholar
  208. Jimenez RE, Eble JN, Reuter VE, Epstein JI, Folpe AL, de Peralta-Venturina M, Tamboli P, Ansell ID, Grignon DJ, Young RH, Amin MB (2001) Concurrent angiomyolipoma and renal cell neoplasia: a study of 36 cases. Mod Pathol 14: 157–63PubMedCrossRefGoogle Scholar
  209. Jocham D, Richter A, Hoffmann L, Iwig K, Fahlenkamp D, Zakrewski G, Schmitt E, Danneberg T, Lehmacher W, von Wietersheim J Doehn C (2004) Adjuvant autologous renal cell vaccine in patients with renal cell carcinaoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 363: 594–599PubMedCrossRefGoogle Scholar
  210. Johnson CD, Donnick NR, Cohan RH et al. (1987) Renal adenocarcinoma: CT staging of 100 tumors. Am J Roentgenol 148(1): 59–63Google Scholar
  211. Kang DE, White RL, Zuger JH, Sasser HC, Teigland CM (2004) Clinical use of fluorodeoxyglucose F18 positron emission tomography for detection of renal cell carcinoma. J Urol 171: 1806–1809PubMedCrossRefGoogle Scholar
  212. Kantor AF (1977) Currant concepts in the epidemiology and etiology of primary renal cell carcinoma. J Urol 117: 415–417PubMedGoogle Scholar
  213. Karakiewicz PI, Suardi N, Jeldres C, Audet P, Ghosn P, Patard JJ, Perrotte P (2008) Neoadjuvant sutent induction therapy may effectively downstage renal cell carcinoma atrial thrombi. Eur Urol 53: 845–848PubMedCrossRefGoogle Scholar
  214. Karakiewicz PI, Briganti A, Chun FK, Trinh QD, Perrotte P, Ficarra V, Cindolo L, de la Tialle A, Tostain J, Mulders PF, Salomon L, Zigeuner R, Prayer-Galetti T, Chautard D, Valeri A, Lechevallier E, Descotes JL, Lang H, Mejean A, Patard JJ (2007) Multi-institutional validation of a new renal cancer-specific survival nomogram. J Clin Oncol 25: 1316–1322PubMedCrossRefGoogle Scholar
  215. Karakiewicz PI, Trinh QD, Bhojani N, Bensalah K, Salomon L, de la Taille A, Tostain J, Cindolo L, Altieri V, Ficarra V, Schips L, Zigeuner R, Mulders PFA, Valeri A, Descotes JL, Mejean A, Patard JJ (2007) Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease: prognostic indicators of disease-specific survival. Eur Urol 51: 1616–1624PubMedCrossRefGoogle Scholar
  216. Kattan MW, Reuter V, Motzer RJ, Katz J, Russo P (2001) A postoperative prognostic nomogram for renal cell carcinoma. J Urol 166 (1): 63–67PubMedCrossRefGoogle Scholar
  217. Kavoussi IR, Kerbl K, Capelouto CC, McDougall EM, Glayman RV (1993) Laparoscopic nephrectomy for renal neoplasms. Urology 42: 603–609PubMedCrossRefGoogle Scholar
  218. Kawai K, Saijo K, Oikawa T, Ohno T, Akaza H (2004) Enhancement of T cell proliferative response against autologous cancer cells of a metastatic renal cell carcinoma patient after unexplained regression. Int J Urol 12: 1130–1132CrossRefGoogle Scholar
  219. Kerbl K, Clayman RV, McDougall et al. (1994) Transperitoneal nephrectomy for benign disease of the kidney: a comparison of laparoscopic and open surgical techniques. Urology 43: 607–613PubMedCrossRefGoogle Scholar
  220. Kierney PC, van Heerden JA, Segura JW, Weaver AL (1994) Surgeon’s role in the management of solitary renal cell carcinoma metastases occurring subsequent to initial curative nephrectomy: an institutional review. Ann Surg Oncol 1: 345–52PubMedCrossRefGoogle Scholar
  221. Kim HL, Zisman A, Han KR, Figlin RA, Belldegrun AS (2004a) Prognostic signifi-cance of venous thrombus in renal cell carcinoma. Are renal vein and inferior cave involvement different. J Urol 171: 588–591PubMedCrossRefGoogle Scholar
  222. Kim JK, Park SY, Shon JH, Cho KS (2004b) Angiomyolipoma with minimal fat: differentiation from renal cell carcinoma at biphasic helical CT. Radiology 230: 677–84PubMedCrossRefGoogle Scholar
  223. Kim HL, Seligson D, Liu X Janzen N, Bui MH, Yu H, Shi T, Belldegrun AS, Horvath S, Figlin RA (2005) Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma. J Urol 173: 1496–1501PubMedCrossRefGoogle Scholar
  224. Klatte T, Patard JJ, Wunderlich H, Goel RH, Lam JS, Junker K, Schubert J, Böhm M, Allhoff EP, Kabbinavar FF, Crepel M, Cindolo L, de la Taille A, Tostain J, Mejean A, Soulie M, Bellec L, Bernhard JC, Ferriere JM, Pfister C, Albouy B, Colombel M, Zisman A, Belldegrun AS, Pantuck AJ (2007) Metachronous bilateral renal cell carcinoma: risk assessment, prognosis and relevance of the primary-free interval. J Urol 177: 2081–2087PubMedCrossRefGoogle Scholar
  225. Klatte T, Patard JJ, de Martino M, Bensalah K, Verhoest G, de la Taille A, Abbou CC, Allhoff EP, Carrierei G, Riggs SB, Kabbinavar FF, Bell Degrun AS, Pantuck AJ (2008) Tumor size does not predict risk of metastatic disease or prognosis of small renal cell carcinomas. J Urol 179: 1719–1726PubMedCrossRefGoogle Scholar
  226. Kletscher BA, Quian J, Bostwick DG, Blute MI, Zincke H (1996) Prospective analysis of the incidence of ipsilateral adrenal metastasis in localized renal cell carcinoma. J Urol 155: 1844PubMedCrossRefGoogle Scholar
  227. Kopka L, Fischer U, Zoeller G, Schmidt C, Ringert RH, Grabbe E (1997) Dual-phase helical CT of the kidney: value of the conticomedullary and nephrographic phase for evaluation of renal lesions and preoperative staging of renal cell carcinoma. AJR Am J Roentgenol. 169: 1573–8PubMedGoogle Scholar
  228. Kovacs G, Brusa P, de Riese W (1989) Tissue-specific expression of a constitutional 3; 6 translocation: development of multiple bilateral renal-cell carcinomas. Int J Cancer 43: 422–427PubMedCrossRefGoogle Scholar
  229. Kovacs G, Fuzesi L, Emanuel A, Kung F (1991) Cytogenetics of papillary renal cell tumors. Genes, chromosome & cancer 3: 249–255CrossRefGoogle Scholar
  230. Kuczyk M, Wegener G, Jonas U (2005) The therapeutic value of adrenalectomy in case of solitary metastatic spread originating from primary renal cell cancer. Eur Urol 48 (2): 252–7PubMedCrossRefGoogle Scholar
  231. Kuczyk MA, Köhn G, Höfner K, Machtens S, Bokermeyer C, Stief CG, Truss MC, Schäfers HJ, Hartmann JT, Jonas U (1998) Prognostische Relevanz des Kavathrombus beim Nierenzellkarzinom. Urologe A 37: 299–305PubMedCrossRefGoogle Scholar
  232. Kuhn FP, Altwein JE (1980) Nierenadenome: Dignität, Klinik und Therapie: Urol Int 35: 258–270PubMedCrossRefGoogle Scholar
  233. Kühn R, Bornhof Ch, Giedl J (1991) Klinik und Wertigkeit renaler Onkozytome. Urologe A 30: 357–340Google Scholar
  234. Kumar S, Dugue JL, Guimaraes KC, Dicanzio J, Loughlin KR, Richie JP (1991) Short and long-term morbidity of thoracoabdominal incision for nephrectomy: a comparison with the flank approach. J Urol 162 (6): 1927–9Google Scholar
  235. Kunkle DA, Crispen PL, Li T, Uzzo RG (2007) Tumor size predicts synchronous metastatic renal cell carcinoma: implications for surveillance of small renal masses. J Urol 177: 1692–1697PubMedCrossRefGoogle Scholar
  236. Kunkle DA, Greenberg RE, Chen DYT, Uzzo RG (2007) Clinical characteristics of enhancing renal masses which do not demonstrate interval growth. J Urol 177: 849–854PubMedCrossRefGoogle Scholar
  237. Lager DJ, Slagel DD, Palechek PL (1994) The experience of epidermal growth factor receptor and transforming growth factor alpha in renal cell carcinoma. Mod athol 7: 544–548Google Scholar
  238. Lam CW, To KF, Tong SF (2006) Genome-wide detection of allelic imbalance in renal cell carcinoma using high-density single-nucleotide polymorphism microarrays. Clin Biochem 39 (3): 187–90PubMedCrossRefGoogle Scholar
  239. Lam JS, Klatte T, Patard JJ, Goel RH, Guille F, Lobel B, Abbou CC, de la Taille A, Tostain J, Cindolo L, Altieri V, Ficarra V, Artibani W, Paryer-Galetti T, Schips L, Zigeuner R, Pantuck AJ, Figlin RA, Belldegrun AS (2007) Prognostic relevance of tumour size in T3a renal cell carcinoma: a multicentre experience. Eur Urol 52: 155–162PubMedCrossRefGoogle Scholar
  240. Lam JS, Klatte T, Kim HL, et al. (2008) Prognostic factors and selection for clinical studies of patients with kidney cancer. Crit Rev Ondol/Hematol 65:235–262Google Scholar
  241. Lane BR, Samplaski MK, Herts BR et al. (2008) Renal mass biopsy — a renaissance? J Urol 179: 20–27PubMedCrossRefGoogle Scholar
  242. Latif F, Tory K, Gnarra J, Yao M, Duh FM, Orcutt ML, Stackhouse T, Kuzmin I, Modi W, Geil L, Schmidt L, Zhou F, Li H, Wei MH, Chen F, Glenn G, Choyke P, McClellan MW, Weng Y, Duan DSR, Dean M, Glavac D, Richards FM, Crossey PA, Ferguson-Smith MA, Le Paslier D, Chumakov Ilya, Cohen D, Chinault AC, Maher ER, Linehan WM, Zbar B, Lerman MI (1993) Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260: 1317–20PubMedCrossRefGoogle Scholar
  243. Lau WK, Blute ML, Weaver AL, Torres VE, Zincke H (2000) Matched comparison of radical nephrectomy vs nephron-sparing surgery in patients with unilateral renal cell carcinoma and noraml contralateral kidney. Mayo Clin Proc. 75: 1236–1242PubMedCrossRefGoogle Scholar
  244. Launonen V, Vierimaa O, Kiuru M, Isola J, Roth S, Pukkala E et al. (2001) Inherited susceptibility to uterine leiomyomas and renal cell cancer. Proc Natl Acad Sci USA 98: 3387PubMedCrossRefGoogle Scholar
  245. Law CH, Wei AC, Hanna SS et al. (2003) Pancreatic resection for metastatic renal cell carcinoma. Presentation, treatment, and outcome. Ann Surg Oncol 10: 922–926PubMedCrossRefGoogle Scholar
  246. Lawatsch EJ, Langenstroer P, Byrd GF, See WA, Quiroz FA, Begun FP (2006) Intermediate results of laparoscopic cryoablation in 59 patients at the Medical college of Wisconsin. J Urol 175: 1225–1229PubMedCrossRefGoogle Scholar
  247. Lawrentschuk N, Davis ID, Bolton DM, Scott AM (2006) Positron emission tomography (PET), immuno-PET and radioimmunotherapy in reanal cell carcinoma: a developing diagnostic and therapeutic relationship. BJU International 97: 916–922PubMedCrossRefGoogle Scholar
  248. Lebret T, Poulain JE, Moilinie V et al. (2007) Percutaneous core biopsy for renal masses. Indication, accuracy and results: J Urol 178: 1184–1188.PubMedCrossRefGoogle Scholar
  249. Lee SE, Kim HH (1994) Validity of kidney-preserving surgery for localized renal cell carcinoma. Eur Urol 25: 204–208PubMedGoogle Scholar
  250. Leibovich B, Blute MI, Cheville JC, Lohse CM, Frank I, Kwon ED, Weaver AL, Parker AS, Zincke H (2003) Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma. Cancer 97: 1663–1671PubMedCrossRefGoogle Scholar
  251. Leibovich BC, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H (2004) Nephron sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm. Results in outcome similar to radical nephrectomy. J Urol 171: 1066–70PubMedCrossRefGoogle Scholar
  252. Leibovich BC, Cheville JC, Lohse CM, Zincke H, Frank I, Kwon ED, Merchan JR, Blute ML (2005) A scoring algorithm to predict survival for patients with metatatic clear cell carcinoma: a stratification tool for prospective clinical trials. JUrol 174: 1759–1763Google Scholar
  253. Lendvay TS, Marshall FF (2003) The tuberous sclerosis complex and ist highly variable manifestations. J Urol 169: 1635–1642PubMedCrossRefGoogle Scholar
  254. Lerner et al. (1996) Disease outcome in patients with low stage renal cell carcinoma treated with nephron sparing or radical surgery. J Urol 155:1868–1873PubMedCrossRefGoogle Scholar
  255. Levens W, Rübben H, Ingenhag W (1989) Long-term interferon treatment in metastativ renal cell carcinoma. Eur Urol 16: 378–381PubMedGoogle Scholar
  256. Levi F, Lucchini F, Negri E, La Vecchia C (2004) Declinino mortalità from kidney cancer in Europe. Ann Oncol 15 (7): 1130–5PubMedCrossRefGoogle Scholar
  257. Levine E, Slusher SL, Grantham JJ et al. (1991) Natural history of acquired renal cystic disease in dialysis patients. Am J Roentgenol 156: 501–506Google Scholar
  258. Levine E (1992) Renal cell carcinoma in uremic acquired renal cystic disease: incidence, detection and management. Urologic Radiol 13: 203–210CrossRefGoogle Scholar
  259. Levinson AK, Johnson DE, Strong IC, Pathak S, Huff V, Saunders CF (1990) Faminal renal cell carcinoma: hereditary or coincidental? J Urol 144: 849–851PubMedGoogle Scholar
  260. Levinson AD, Su LM, Agarwal D, Sroka M, Jarrett TW, Kavoussi LR, Solomon SB (2008) Long-term oncological and overall outcomes of percutaneous radio frequency ablation in high risk surgical patients with a solitary small renal mass. J Urol 180: 499–504PubMedCrossRefGoogle Scholar
  261. Li G, Feng G, Gentil-Perret A, Genin C, Tostain J (2008) Serum carbonic anhydrase 9 level is associated with postoperative recurrence of conventional renal cell cancer. J Urol 180: 510–514PubMedCrossRefGoogle Scholar
  262. Li FP, Decker HJH, Zbar B, Stanton VP, Kovacs G, Seizinger BR, Aburatani H, Sandberg AA, Berg S, Hosoe S, Brown RS (1993) Clinical and genetic studies of renal cell carcinomas in a family with a constitutional chromosome 3; 8 translocation. Annals of Internal Medicien 118: 106–11Google Scholar
  263. Licht MR, Novick AC, Goormastic M (1994) Nephron sparing surgery in incidental versus suspected renal cell carcinoma. J Urol 152: 39–42PubMedGoogle Scholar
  264. Lien YHH, Kam I, Shanley PF, Schröter GPJ (1991) Metastatic renal cell carcinoma associated with acquired cystic kidney disease 15 years after successful renal transplantation. Am J Kidney Dis 6: 711–715Google Scholar
  265. Lindblad P (2004) Epidemiology of renal cell carcinoma. Scand J Surg 93 (2): 88–96PubMedGoogle Scholar
  266. Linehan WM, Grubb RL, Coleman JA, Zbar B, McClellan MW (2005) The genetic basis of cancer of kidney cancer: implications for genespecific clinical management. BJU Int J 95 (Suppl 2): 2–7CrossRefGoogle Scholar
  267. Ljungberg B, Stenlig R, Roos C (1986) Prognostik value of deoxyribonucleic acid analysis in state I renal cell carinoma. J Urol 136: 801–814PubMedGoogle Scholar
  268. Ljungberg B, Holmberg G, Sjödin JG, Hietala SO, Stenling R (1990) Renal cell carcinoma in a renal cyst: a case report and review of the literature. J Urol 143: 797–799PubMedGoogle Scholar
  269. Ljungberg B, Larsson P, Stenling R, Roos G (1991) Flow cytometric desyribonucleic acid analysis in stage I renal cell carcinoma. J Urol 146: 697–699PubMedGoogle Scholar
  270. Ljunberg B, Hanbury DG, Kuczyk MA, et al. (2007) Renal cell carcinoma guidelines. Eur Urol 51: 1502–1510CrossRefGoogle Scholar
  271. Lonser R, Glenn G, Walther MM et al. (2003) Von Hippel-Lindau disease. Lancet 361: 2059–67PubMedCrossRefGoogle Scholar
  272. Lopez-Beltran A, Scarpelli M, Montironi R, Kirkali Z (2006) WHO classification of the renal tumors of the adults. European Urology 49: 798–805PubMedCrossRefGoogle Scholar
  273. Lucas SM, Stern JM, Adibi M, Zelster IS, Cadeddu JA, Raj GV (2008) Renal function outcomes in patients treated for renal masses smaller than 4 cm by ablative and exstirpative techniques. J Urol 179: 75–80PubMedCrossRefGoogle Scholar
  274. Maher ER, Iselius L, Yates JRW, Littler M, Benjamin C, Harris R, Sampson J, Williams A, Ferguson-Smith MA, Morton N (1991) Von Hippel-Lindau disease: a genetic study. J Med Genet 28: 443–7PubMedCrossRefGoogle Scholar
  275. Mahnken HA, Tacke J (2006) Renal tumors. Recent results Cancer Res 167: 123–133PubMedCrossRefGoogle Scholar
  276. Mahnken AH, Rhode D, Brkovic D, Günther RW, Tacke JA (2005) Percutaneous radiofrequency ablation of renal cell carcinoma: prelimnary results. Acta Radiol 46: 208–214PubMedCrossRefGoogle Scholar
  277. Malek RS, Omess PJ, Benson RC Jr, Zinke H (1987) Rehal cell carcinoma in von Hippel-Lindau-Syndrome. Am J Med 82: 236–240PubMedCrossRefGoogle Scholar
  278. Maloney KE, Norman RW, Lee CLY, Millard OH, Welch JP (1991) Cytogenetic abnormalities associated with renal cell carcinoma. J Urol 146: 692–696PubMedGoogle Scholar
  279. Maranchie JK, Alfonso A, Albert P et al. (2004) Solid renal tumor severity in von Hippel-Lindau disease is related to germline delection length and location. Human Mutation 23: 40–6PubMedCrossRefGoogle Scholar
  280. Marberger M (1988) Organerhaltende Nierentumorexzision. Akt Urol 19 (2): 58–66CrossRefGoogle Scholar
  281. Marcus SG, Choyke PL, Reiter R, Jaffe GS, Alexander RB, Linehan WM, Rosenberg SA, Walther MM (1993) Regression of metastatic renal cell carcinoma after cytoreductive nephrectomy. J Urol 150: 463–6PubMedGoogle Scholar
  282. Margulis V, Matin SF, Tannir N, Tamboli P, Swanson DA, Jonasch E, Woods CG (2008) Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell Carcinoma. J Urol 180: 94–98PubMedCrossRefGoogle Scholar
  283. Marshall FF, Ferguson J, Reitz BA (1990) Operative management of renal cell carcinoma with suprahepative intracaval neoplastic extension. Eur Urol 18 (2): 26–28PubMedGoogle Scholar
  284. Marshall FF, Powell KC (1982) Lymphadenectomy for renal cell carcinoma: anatomical and therapeutic considerations. J Urol 128: 677–681PubMedGoogle Scholar
  285. Marshall FF (1993) Editorial comment. J Urol 150: 323Google Scholar
  286. Marten A, Renoth S, Heinicke T, Albers P, Pauli A, Mey U, Caspari R, Flieger D, Hanfland P, Von Ruecker A, Eis-Hubinger AM, Muller S, Schwaner I, Lohmann U, Heylmann G, Sauerbruch T, Schmidt-Wolf IG (2003) Allogenetic dendritic cells fudes with tumor cells: preclinical results and outcome of a clinical phase I/II triall in patients with metastatic renal cell carcinoma. Hum Gene Ther 14 (5): 483–494PubMedCrossRefGoogle Scholar
  287. Matson MA, Cohen EP (1990) Acquired cystic kidney disease: occurence, prevalence and renal cancers. Medicine 69 (4): 217–226PubMedCrossRefGoogle Scholar
  288. Mattar K, Bosiuk J, Finelli A, et al. (2008) Active surveillance of small renal masses: a prospective multic-centre Canadian traial. Eur J Urol 7 (Suppl3): 309CrossRefGoogle Scholar
  289. Maturen KE, Nghiem HV, Caoili EM et al. (2007) Renal mass core biopsy: accuracy and impact on clinical management. Am J Roentgenol 188: 563–570CrossRefGoogle Scholar
  290. Mayo-Smith WW, Dupuy DE, Parikh PM, Pezzullo JA, Cronan JJ (2003) Image-guided percutaneous radiofrequency ablation of solid renal masses: techniques and outcomes of 38 treatment sessions in 32 consecutive patients. Am J Roentgenol 180:1503–1508Google Scholar
  291. McCabe M, Stablein D, Hawkins MJ (1991) The modified Group C experience — phase III randomized trials of IL-2 versus IL-2/LAK in advanced renal cell cancer and advanced melanoma [abstract 714]. Proceedings of the American Society of Clinical Oncology 10: 213Google Scholar
  292. McCune CS, Schapira DV, Henshaw EC (1981) Specific immunotherapy or advances renal cell carcinoma: evidence for the polyclonality of metastases. Cancer 47: 1984–1987PubMedCrossRefGoogle Scholar
  293. McDermott DF, Regan MM, Clark J et al. (2005) Randomized phase III trial of high-dose interleukin-2 versus subcutaneous IL-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 23 (1): 133–141PubMedCrossRefGoogle Scholar
  294. McDonald JC, McDonald AD, Hughes JM, Rando RJ, Weill H (2005) Mortality from lung and kidney disease in a cohort of North American industrial sand workers: an update. Ann Occup Hyg 49 (5): 367–73PubMedCrossRefGoogle Scholar
  295. McLaughlin JK, Blot WJ, Devesa SS, Fraumeni JF Jr. (1996) Renal cancer. In: Schottenfeld D, Fraumeni JF Jr. (eds) Cancer Epidemiology and Prevention. 2nd edn. New York, NY: Oxford University Press, pp 1142–1155Google Scholar
  296. McKiernan J, Yossepowitch O, Kattan MW, Simmons R, Motzer RJ, Reuter VE, Russo P (2002) Partial nephrectomy for renal cortical tumors: pathologic findings and impact on outcome. Urology 60: 1003–9PubMedCrossRefGoogle Scholar
  297. McNichols DW, Segura JW, DeWeerd JH (1981) Renal cell carcinoma: long-term survival and late recurrence. J Urol 126: 17–23PubMedGoogle Scholar
  298. Mekhail TM, Abou-Jawde RM, Boumerhi G, Malhi S, Wood L, Elson P, Bukowski R (2005) Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 23: 832–841PubMedCrossRefGoogle Scholar
  299. Mellemgaard A, Moller H, Olsen J, Jenson O (1991) Increased risk of renal cell carcinoma in obese women. J Natl Cancer Inst 83: 1581PubMedCrossRefGoogle Scholar
  300. Messing EM, Manola J, Wilding G, et al. (2003) Phase III study of interferon alfa-NL as adjuvant for respectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol 21: 1214–1222PubMedCrossRefGoogle Scholar
  301. Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R; European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group (2001) Radical nephrectomy plus interferonalfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358: 966–70PubMedCrossRefGoogle Scholar
  302. Middleton RG, Presto AJ (1973) Radical thoracoabdominal nephrectomy for renal cell cancer. J Urol 110: 36PubMedGoogle Scholar
  303. Middleton RG (1967) Surgery for metastatic renal cell carcinoma. J Urol 97: 973–977PubMedGoogle Scholar
  304. Milowsky MI, Rosmarin A, Tickoo SK, Papanicolaou N, Nanus DM (2002) Active chemotherapy for collecting duct carcinoma of the kidney: a case report und reviwe of the literature. Cancer 94: 111–116PubMedCrossRefGoogle Scholar
  305. Mittelmann A, Hubermann M, Puccio C et al. (1990) A phase I study of recombinant human interleukin-2 and alpha-interferon-2a in patients with renal cell cancer, colorectal cancer, and malignant melanoma. Cancer 66: 664–669CrossRefGoogle Scholar
  306. Miyao N, Masiumori N, Takahasi H et al. (1998) Lymph node metastasis in patients with carcinoma of the renal pelvis and ureter. Eur Urol 33: 180–185PubMedCrossRefGoogle Scholar
  307. Moch H, Gasser T, Amin MB, Torhorst J, Sauter G, Mihatsch MJ (2000) Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma: a Wisss experience with 588 tumors. Cancer 89: 604–614PubMedCrossRefGoogle Scholar
  308. Moinzadeh A, Gill IS, Finelli A, Kaouk J, Desai M (2006) Laproscopic partial nephrectomy: 3-year follow-up. J Urol 175: 459–462PubMedCrossRefGoogle Scholar
  309. Moinzadeh A, Libertino JA (2004) Prognostic significance of tumor thrombus level in patients with renal cell carcinoma and venous tumor thrombus extension. Is all T3b the same. J Urol 171: 598–601PubMedCrossRefGoogle Scholar
  310. Moll V, Becht E, Zieler M (1993) Kidney preserving surgery in renal cell tumors: indications, technique and results in 152 patients. J Urol 150: 319–323PubMedGoogle Scholar
  311. Möller JD, Esteve J, Möller H, Renrd H (1990) Cancer in the European Community and ist member states. Eur J Cancer 6(11/12): 1167–1256Google Scholar
  312. Montie JE, Novick AC (1988) Partial nephrectomy for renal cell carcinoma. J Urol 140: 129–130PubMedGoogle Scholar
  313. Montie JE, Stewart BH, Straffon RA, Banowsky LHW, Hewitt CB, Montague DK (1977) The role of adjunctive nephrectomy in patients with metastatic renal cell carcinoma J Urol 117: 272–275PubMedGoogle Scholar
  314. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J (1999) Survival and prognosis stratification of 670 patients with advances renal cell carcinoma. J Clin Oncol 17 (8): 2530–2540PubMedGoogle Scholar
  315. Motzer RJ, Bacik J, Murphy BA, Russo P, Pazumdar M (2002) Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20: 289–296PubMedCrossRefGoogle Scholar
  316. Motzer RJ, Bacik J, Mariani T et al. (2002) Treatment outcome and survival with metastatic renal cell carcinoma of non-clear cell histology. J Clin Oncol 20 (9): 2376–2381PubMedCrossRefGoogle Scholar
  317. Motzer RJ, Bander NH, Nanus DM (1996) Renal cell carcinoma. N Engl J Med 335: 865–875PubMedCrossRefGoogle Scholar
  318. Motzer RJ, Mihcaelson MD, Redman BG et al. (2006) Activity of SU 11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell cardinoma. J Clin Oncol 24 (1): 16–24PubMedCrossRefGoogle Scholar
  319. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski OR, Qudard S, Kim ST, Baum CM, Figlin RA (2007) Sunitinib versus interferon alfa in metastatic renal cell carcinoma. N Eng J Med 356: 115–124CrossRefGoogle Scholar
  320. Murphy BR, Rynard SM, Pennington KL, Grosh W, Loehrer PJ (1994) A phase II trial of vinblastine plus dipyrimadole in advanced renal celllcarcinoma. Am J Clin Oncol 17: 10–13PubMedCrossRefGoogle Scholar
  321. Muss HB (1987) Interferon therapy for renal cell carcinoma. Semin Oncol 14 (2): 34–42Google Scholar
  322. Nadler RB, Loeb S, Clements JQ, Batler RA, Gonzalez CM, Vardi IY (2006) A prospective study of laparoscopic radical nephrectomy for T1-tumors — Is transperitoneal, retroperitoneal or hand assited the best approach? J Urol 175: 1230–1234PubMedCrossRefGoogle Scholar
  323. Naito S, Kimiya K, Sakamoto N et al. (1991) Prognostic factors and value of adjunctive nephrectomy in patients with state IV renal cell carcinoma. Urology 37: 95–99PubMedCrossRefGoogle Scholar
  324. Nambirajan T, Jeschke S, Al-Zahrani H, Vrabes G, Leeb K, Janetschek G (2004) Prospective randomized controlled study: transperitoneal laparoscopic versus retroperitoneoscopic radical nephrectomy. Urology 64: 919–924PubMedCrossRefGoogle Scholar
  325. Nanus DM, Garino A, Milowsky MI, Larkin M, Dutcher JP (2004) Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma. Cancer 101 (7): 1545–51PubMedCrossRefGoogle Scholar
  326. Negrier S, Caty A, Lesimple T, Doullard JY, Escudier B, Rossi JF, Viens P, Gomez F for the Groupe Francais d’Immunothérapie, Fédération Nationale des Centres de Lutte Contre le Cancer (2000) Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. J Clin Oncol 18: 4009–4015PubMedGoogle Scholar
  327. Negrier S, Escudier B, Lasset C et al. (1998) Recombinat human interleukin-2, recombinant human interferon alfa-2a, or both in metastativ renal-cell carcinoma. N Engl J Med 338: 1272–1278PubMedCrossRefGoogle Scholar
  328. Neri B, Doni L, Gemelli MT, Fulignati C, Turrini M, Di Cello V, Dominici A, Maleci M, Mottola A, Ponichietti R, Raugei A, Valsuani G, Cini G (2002) Phase Il trial of weekly intravenoud gemcitabine administratiojn with interferon and interleukin-2 immunotherapy for metastatic renal cell cancer. J Urol 168: 956–958PubMedCrossRefGoogle Scholar
  329. Neuhaus C, Dijkhuizen T, van den Berg E et al. (1997) Involvement of the chromosomal region 11q13 in renal oncocytoma: case report and literature review. Cancer Genet Cytogenes 94: 95–98CrossRefGoogle Scholar
  330. Neumann HPH, Wiestler OD (1991) Clustering of features of von Hippel-Lindau syndrome: evidence for a complex genetic locus. Lancet 337: 1052–54PubMedCrossRefGoogle Scholar
  331. Neves RJ, Zincke H, Taylor WF (1988) Metastatic renal cell cancer and radical nephrectomy: identification of prognostic factors and patient survival. J Urol 139: 1173–1176PubMedGoogle Scholar
  332. Nguyen CT, Lane BR, Kaou JH, Hegarty N, Gill IS, Novick AC, Camphell SC (2008) Surgical salvage of renal cell carcinoma recurrence after thermal ablative therapy. J Urol 180: 104–109PubMedCrossRefGoogle Scholar
  333. Nickerson ML, Warren MB, Toro JR et al. (2002) Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dube syndrome. Cancer Cell 2: 157–64PubMedCrossRefGoogle Scholar
  334. Novick AC, Streem S, Montic JE, Pontes JE, Siegel S, Montague DK, Goormastic M (1989) Conservative surgery for renal cell carcinoma: a single-center experience with 100 patients. J Urol 141: 835–839PubMedGoogle Scholar
  335. Novick AC (1991) Possibilities and limitations of partial nephrectomy for renal cell carcinoma. Curr Opin Urol 1: 30–3CrossRefGoogle Scholar
  336. Nurmi MJ, Puntala PV, Tyrkko JE, Antila LE (1985) Transabdominal and lumbar nephrectomy for renal adenocarcinoma. Scand J Urol Nephrol 19 (2): 129–31PubMedCrossRefGoogle Scholar
  337. O’Dea et al. (1978) The treatment of renal cell carcinoma with solitary metastasis. J Urol 120: 540–542PubMedGoogle Scholar
  338. Ogan K, Cadeddu JA, Stifelman MD (2003) Laparoscopic radical nephrectomy: oncologic efficacy. Urol Clin N Am 30: 543–550CrossRefGoogle Scholar
  339. Ogawa O, Habuchi T, Kaheki Y, Koshiba M, Sugiyana, Yoshida O (1952) Allelic losses at chromosome 17p in human renal cell carcinoma are inversely related to allelic losses at chromosome 3p1. Cancer Research 52: 1881–85Google Scholar
  340. Ono Y, Kinukawa T, Hattori R (1999) Laparoscopic radical nephrectomy for renal cell carcinoma: a five year experience. Urology 53: 280–286PubMedCrossRefGoogle Scholar
  341. Oosterwijk-Wakka C, Tiemessen DM, Bleumer I, de Vries IJ, Jongmans W, Adema GJ, Debruynce FM, de Mulder PH, Oosterwijk E, Mulders PE (2002) Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: a phase I study. J Immunother 25: 500–508PubMedCrossRefGoogle Scholar
  342. Paganini-Hill A, Ross RK, Henderson BE (1988) Epidemiology of renal cancer. In: Skinner DG, Lieskovksy G (eds) Treatment of genitourinary cancer, Saunders, PhiladelphiaGoogle Scholar
  343. Pahernik S, Roos F, Wiesner C, Thüroff JW et al. (2007a) Nephron sparing surgery for renal cell carcinoma in solitary kidney. Wold J Urol 25: 513–517CrossRefGoogle Scholar
  344. Pahernik S, Cudovic D, Roos F et al. (2007b) Bilateral synchronous sporadic renal cell carcinoma: surgical management, oncological and functional outcomes. BJU Int 100: 26–29PubMedCrossRefGoogle Scholar
  345. Pantuck AJ, Zisman A, Belldegrun AS (2001) Biology of renal cell carcinoma: chaning concepts in classification and staging. Semin Urol Oncol 19 (2): 72–79PubMedGoogle Scholar
  346. Pantuck AJ, Zisman A, Dorey F, Chao DH, Han KR, Said J, Gitlitz B, Belldegrun AS, Figlin RA (2003) Renal cell carcinoma with retroperitoneal lymph nodes. Impact on survival and benefits of immunotherapy. Cancer 97: 2995–3002PubMedCrossRefGoogle Scholar
  347. Pantuck AJ, Zisman A, Dorey F, Chao DH, Han KR, Said J, Gitlitz BJ, Figlin RA, Belldegrun AS (2003) Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection. J Urol 169: 2076–83PubMedCrossRefGoogle Scholar
  348. Pareek G, Hedican SP Jason RG, Bruskewitz RC, Nakada SY (2006) Meta-Aanlysis of the complications of laparoscopic renal surgery: Comparison of procedures and techniques. J Urol 175: 1208–1213PubMedCrossRefGoogle Scholar
  349. Parek DJ, Lin WC, Herrell SD (2005) Optical spectroscopy characteristics can differentiate benign and malignant renal tissues: a potentially useful modality. J Urol 174: 1754–1758CrossRefGoogle Scholar
  350. Park BK, Kim SH, Choi HJ (2005) Characterization of renal cell carcinoma using agent detection imaging: comparison with gray-scale US. Korean J Radiol 6: 173–8PubMedCrossRefGoogle Scholar
  351. Parker JE, Cerhan JR, Lynch CF, Leibovich BC, Cantor KP (2004) History of urinary tract infection and risk of renal cell carcinoma. Am J Epidemiol 59: 42–48CrossRefGoogle Scholar
  352. Patard JJ, Shvarts O, Lam JS, Pantuck AJ, Kim HL, Ficarra V, Cindolo L, Han KR, de la Taille A, Tostain J, Artibani W, Abbou CC, Lobel B, Chopin DK, Figlin RA, Mulder PF, Belldegrun AS (2004) Safety and efficacy of partial nephrectomy for all T1 tumors based on an international multicenter experience. J Urol 171: 2181–2185PubMedCrossRefGoogle Scholar
  353. Patard JJ (2006) Prognostic and biological significance of lymph node spreading in renal cell carcinoma. Eur Urol 49: 220–222PubMedCrossRefGoogle Scholar
  354. Paul R, Mordhorst J, Busch R et al. (2001) Adrenal sparing surgery during radical nephrectomy in patients with renal cell cancer: a new algorithm. J Urol 166: 59–62PubMedCrossRefGoogle Scholar
  355. Pavlovich CP, Grubb RL 3rd, Hurley K, Glenn GM, Toro J, Schmidt LS, Torres-Cabala C, Merino MJ, Zbar B, Choyke P, Walther MM, Linehan WM (2005) Evaluation and management of renal tumors in the Birt-Hogg-Dube syndrome. J Urol 173 (5): 1482–6 Erratum in: J Urol 174 (2): 796PubMedCrossRefGoogle Scholar
  356. Pavlovich CP, Schmidt LS (2004) Searching for the hereditary causes of nrel-cell carcinoma. Nat Rev Cancer 4: 381–393PubMedCrossRefGoogle Scholar
  357. Pavlovich CP, Walther MM, Eyler RA et al. (2002) Renal tumors in the Birt-Hogg-Dube syndrome. Am J Surg Pathol 26: 1542–1552PubMedCrossRefGoogle Scholar
  358. Perez-Farinos N, Lopez-Abente G, Pastor-Barriuso R (2006) Time trend and age-period-cohort effect on kidney cancer mortality in Europe, 1981–2000. BMC Public Health 6 (1): 199CrossRefGoogle Scholar
  359. Peyromaure M, Thiounn N, Scotte F, Vieillefond A, Debre B, Oudard S (2003) Collecting duct carcinoma of the kidney: a clinicopathological study of 9 cases. J Urol 170: 1138–1140PubMedCrossRefGoogle Scholar
  360. Pfannschmidt J, Hoffmann H, Muley T, Krysa S, Trainer C, Dienemann H (2002) Prognostic factors for survival after pulmonary resection of metastatic renal cell carcinoma. Ann Thorac Surg 74: 1653–1657PubMedCrossRefGoogle Scholar
  361. Pierorazio PM, McKiernan JM, McCann TR, Mohile S, Petrylak D, Benson MC (2007) Outcome after cytoreductive nephrectomy for metastatic renal cell carcinoma is predicted by fractional percentage of tumor volume removed. BJU Int 100: 755–759PubMedCrossRefGoogle Scholar
  362. Piltz S, Meimarakis G, Wichmann MW, Hatz R, Schiildberg FW, Fuerst H (2003) Long-term resultrs after pulmonary resection of renal cell carcinoma metastases. Ann Thorac Sorg 73: 1082–1087CrossRefGoogle Scholar
  363. Piper NY, Bishoff JT, Magee C (2001) Is a 1 cm margin necessary during nephron-sparing surgery for renal cell carcinoma? Urology 58: 849–852PubMedCrossRefGoogle Scholar
  364. Pizzocaro G, Piva I, Salvoni R, di Fronzo G, Ronchi E, Miodini P and the Lombardy Group (1986) Adjuvant medroxyprogesterone acetate and steroid hormone receptors in category Mo renal cell carcinoma. An interim report of a prospective, randomized study. J Urol 135: 18–21PubMedGoogle Scholar
  365. Pizzocaro G, PÖiva L, Colavita M, Ferri S, Artusi R, Boracchi P, Parmiani G, Marubine E (2001) Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study. J Clin Oncol 19 (2): 425–431PubMedGoogle Scholar
  366. Pomer S, Schirrmacher V, Thiele R, Löhrke H, Brkovic D, Staehler G (1995) Tumor response and 4 year survival data of patients with advanced renal cell carcinoma treated with autologous tumor vaccine and subcutaneous τ-II-2 and IFN-alpha 2b. Int J Oncol 6: 947–954Google Scholar
  367. Ponti G, Ponz de LM, Losi L, Di Gregorio C, Benatti P, Pedroni M, Scarselli A, Riegler G, Lembo L, Pellacani G, Seidenari S, Rossi G, Roncucci L (2006) Different phenotypes in Muir-Torre syndrome: clinical and biomolecular characterization in two Italian families. Br J Dermatol 152 (6): 1335–8CrossRefGoogle Scholar
  368. Poppel H van, Bamelis B, Baert L (1997) Elective nephron-sparing surgery for renal cell carcinoma. Eur Urol 6: 8–12Google Scholar
  369. Poston CD, Jaffe GS, Lubensky IA et al. (1995) Characterization of the renal pathology of a familial form of renal cell carcinoma associated with von Hippel-Lindau disease: clinical and molecular genetic implications. J Urol 153: 22–6PubMedCrossRefGoogle Scholar
  370. Pouessel D, Culine S (2008) High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treatd with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor. Eur Urol 53: 376–381PubMedCrossRefGoogle Scholar
  371. Prestl JC Jr, Wilhelm M, Reuter V, Russo P, Motzer R, Waldmann F (2002) Allelit loss on chromosomes 8 and 9 correlates with clinical outcome in locally advanced clear cell carcinoma of the kidney. J Urol 167: 1464–1468CrossRefGoogle Scholar
  372. Provet J, Tessler A, Brown J, Golimbu M, Bosniak M, Morales P (1991) Partial nephrectomy for renal cell carcinoma: indication, results and implications. J Urol 145: 472–476PubMedGoogle Scholar
  373. Pyrhonen S, Salminen E, Lethonen T, Nurmi M, Tammela T et al. (1996) Recxombinant interferon-alpha 2a with vinblastine vs. vinblastine alone in advances renal cell carcinoma. A phase III study. Am, Soc Clin Oncol 15: abstr 614Google Scholar
  374. Pyrhonen S, Salminen E, Rutuu M, Lethonen T, Nurmi M, Tammely T (1999) Prospective randomized trial of interferon-alpha 2a plus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 17: 2859–2867PubMedGoogle Scholar
  375. Rabbani F, Grimaldi G, Russo P (1998) Multiple primary malignancies in renal cell carcinoma. J Urol 160Google Scholar
  376. Rabbani F, Herr HW, Almahmeed T, Russo P (2002) Temporal change in risk of metachronous contralateral renal cell carcinoma: influence of tumor characteristics and demographie factors. J. Clinical Oncol 20 (9): 2370–5CrossRefGoogle Scholar
  377. Rabbani F, Reuter VE, Katz J, Russo P (2000) Second primary malignancies associated with renal cell carcinoma: influence of histological type. Urology 56: 399PubMedCrossRefGoogle Scholar
  378. Rafla S (1970) Renal cell carcinoma: natural history and results of treatment. Cancer 25: 26PubMedCrossRefGoogle Scholar
  379. Rainwater IM, Hosaka Y, Farrow GM, Lieber MM (1987) Well differentiated clear cell renal carcinoma: significance of nuclear deoxyribonucleic acid patterns studied by flow cytometry. J Urol 137: 15–20PubMedGoogle Scholar
  380. Rassweiler J, Henkel IO, Potempa DM, Copcoat MJ, Miller D, Preminger GM, Alken P (1993) Transperitoneal laparoscopic nephrectomy: training, technique, ans results. J Endoruol 7: 505–515CrossRefGoogle Scholar
  381. Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, Gore M, Desai AA, Patnaik A, Xiong HQ, Rowinsky E, Abbruzzese JI, Xia C, Simantov R, Schwartz B, O’Dwyer J (2006) Phase Il Placebo-Controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24 (16): 1–7CrossRefGoogle Scholar
  382. Rathmell K, Amin C, Wallen E, Pruthi R (2008) Neoadjuvant therapy with sorafenib for locally advanced renal cell carcinoma (RCC). ASCO A370Google Scholar
  383. Ravaud A, Delva R, Gomez F et al. (2002) Sucutaneous interleukin-2 and interferon α in the treatment of patients with metastatic renal cell carcinoma — less efficacy compared to intravenous interlukin-2 and interferon α. Results of a multicenter Phase Il trial form the Groupe Francais d’Immunothérapie. Cancer 95 (11): 2324–2330PubMedCrossRefGoogle Scholar
  384. Ravaud A, Dilhuydy MS (2005) Interferon alpha for treatment of advances renal cancer. Expert Opin Biol Ther 5 (6): 749–762PubMedCrossRefGoogle Scholar
  385. Reichelt O, Gajdba M, Chyhrai A, Wunderlich H, Junker K, Schubert J (2007) Ultrasound-guides biopsy of homogenous solid renal masses. Eur Urol 52: 1421–1427PubMedCrossRefGoogle Scholar
  386. Reiter Re, Zbar B, Linehan WM (1993) Molecular genetic studies of renal carcinoma: potential biologic and clinical significance for genitourinary malignancy. In: Walsh PC, Retik AB, Vaughan ED, Stamey TA (eds) Cembell’s Urology: 3th ed. Sauders, Philadelphia, pp 1–15Google Scholar
  387. Rendon RA, Jewett MAS (2006) Expectant management for the treatment of small renal masses. Urol Oncol 24: 62–67PubMedGoogle Scholar
  388. Repassy DL, Becsi A, Tamas G, Weninger T (1999) Comparison of morbidity of lumbar flank approach and transperitoneal approach for radical nephrectomy. Acta Chir Hung 38 (3–4): 311–20PubMedGoogle Scholar
  389. Riccabona M, Szolar D, Preidler K, Uggowitzer M, Kugler C, Dorfler O, Schreyer HH (1999) Renal masses-evaluation by amplitude coded colour Doppler sonography and multiphasic contrast-enhanced CT. Acta Radiol 40: 457–61PubMedCrossRefGoogle Scholar
  390. Rini BI, Vogelzang NJ, Dumas MC, Wade JL 3rd, Taber DA, Stadler WM (2000) Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer. J Clin Oncol 18: 2419–2426PubMedGoogle Scholar
  391. Rini BI, Zimmermann T, Stadler WM, Gajewski TF, Vogelzang NJ (2002) Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinicl results. J Clin Oncol 20: 2017–24PubMedCrossRefGoogle Scholar
  392. Rini BI, Wilding GT, Hudes G, Stadler WM, Kim S, Tarazim JC, Bycott PW, Liau KF, Dutcher JP (2007) Axitinib (AG-013736:AG) in patients (pts) with metastatic renal cell cancer (RCC) refractory to sorafenib. J Clin Oncol 25 (185): 5032Google Scholar
  393. Rini BI, Campbell SC (2007) The evolving role of surgery for advanced renal cell carcinoma in the era of molecular targeted therapy. J Urol 177: 1978–1984PubMedCrossRefGoogle Scholar
  394. Ritchie AWS, Cisholm GD (1983) The natural history of renal carcinoma. Semin Oncol 10: 390–400PubMedGoogle Scholar
  395. Ritchie AWS, Griffiths G, Cook P, Oliver RTD et al. (1998) Alpha interferon improves survival in patients with metastatic renal carcinoma — preliminary results of an MRC randomised controlled trial. Am Soc Clin Oncol abstr. 1194Google Scholar
  396. Rixe O, Bukowski RM, Mihchaelson MD, Wilding G, Huded GR, Bolte O, Motzer RJ, Bycott P, Liau KF, Freddo J, Trask PC, Kim S, Rini BI (2007) Axinitib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol 8: 975–984PubMedCrossRefGoogle Scholar
  397. Robey EL, Schellhammer PE (1986) The adrenal gland and renal cell carcinoma: is ipsi lateral adrenalectomy a necessary component of radical nephrectomy. J Urol 135: 453–457PubMedGoogle Scholar
  398. Robson CJ, Churchill BM, Anderson W (1969) The restuls of radical nephrectomy for renal cell carcinoma. J Urol 101: 297–301PubMedGoogle Scholar
  399. Rohde D, De Mulder PH, Weissbach L, Osieka R, Blatter J, Jakse G (1996) Experimental and clinical efficacy of 2′,2′-difluorodeoxycytidine (gemcitabine) against renal cell carcinoma. Oncology 53: 476–481PubMedCrossRefGoogle Scholar
  400. Rohde D, Thiemann D, Wildberger J, Wolff J, Jakse G (1998) Treatment of renal cell cancer patients with gemcitabine and interferons: antitumor activity and toxicity. Oncol Re 5: 1555–1560Google Scholar
  401. Roos FC, Pahernik S, Elsäßer A, Victor A, Brenner W, Thüroff JW (2008) Imperative organerhaltende Nierentumorchirurgie bei Einzelniere bzw. bilateralen Tumoren. Langzeitergebnisse. Der Urologe 7: 818–823CrossRefGoogle Scholar
  402. Rosenberg SA, Lotze MT, Muul LM et al. (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin alone. N Engl J Med 316: 889–897PubMedCrossRefGoogle Scholar
  403. Rosenberg SA, Lotze MT, Yang JD et al. (1993) Prospective randomized trial of high dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancers. J Nathl Cancer Inst 85: 622CrossRefGoogle Scholar
  404. Rosenberg SA, Spiess P, Lafreniere R (1986) A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233: 1318–1321PubMedCrossRefGoogle Scholar
  405. Rosenthal EI, Kraft R, Zingg EJ (1984) Organ-preserving surgery in renal cell carcinoma: tumor enucleation versus partial kidney resection. Eur Urol 10: 222–228PubMedGoogle Scholar
  406. Rosser CJ, McCullough DL, Hall MC (2000) Thoracoabdominal radical nephrectomy: is a postoperative thoractomy tube necessary? Urology 55 (6): 847–51PubMedCrossRefGoogle Scholar
  407. Roth JS, Rabinowitz AD, Benson M et al. (1993) Bilateral renal cell carcinoma in the Birt-Hogg-Dube syndrome. J Am Acad Dermatol 20: 1055–58CrossRefGoogle Scholar
  408. Ruiz JL, Vera C, Server G, Osca JM, Boronat F, Jimenez Cruz JF (1991) Renal cell carcinoma: late recurrence in 2 cases. Eur Urol 20: 167–169PubMedGoogle Scholar
  409. Sablin MP, Bouaita L, Balleyguier G et al. (2007) Sequential use of sorafenib and sunitinib in renal cancer: retrospective analysis in 90 patients: Proc Am Soc Clin Oncol J Clin Oncol 25: 5038Google Scholar
  410. Sagalowsky AK, Kadesky KT, Ewatt DM et al. (1994) Factors influencing adrenal metastasis in renal cell carcinoma. J Urol 151: 1181–1184PubMedGoogle Scholar
  411. Sanchez de la Muela P, Zudaire JJ, Robles JE et al. (1991) Renal cell carcinoma: vena cava invasion and prognostic factors. Eur Urol 19: 284–290PubMedGoogle Scholar
  412. Sanchez Y, El-Naggar A, Pathak S, McNeill Killary A (1994) A tumor suppressor locus with 3p14-p12 mediates rapid cell death of renal cell carcinoma in vivo. Genetics 91: 3383–87Google Scholar
  413. Sanchez Y, El-Naggar A, Pathak S, Killary AM (1994) A tumor suppressor, locus within 3p14-p12 mediates rapid cell death of renal cell carcinoma in vivo. Proc Natl Acad Sci USA 91: 3383PubMedCrossRefGoogle Scholar
  414. Sandlund J, Oosterwijk E, Grankvist K, Oosterwijk-Wakka J, Ljungberg B, Rasmuson T (2007) Prgnostic impact of carbonic anhydrase IX expression in human renal cell carcinoma. BJU Int 100: 556–560PubMedCrossRefGoogle Scholar
  415. Sardock DS, Settel AP, Resnick MI (1995) A new protocol for follow-up of renal cell carcinoma based pathological stage. J Urol 154: 28CrossRefGoogle Scholar
  416. Sarna G, Figlin R, de Kernion J (1987) Interferon in renal cell carcinoma. The UCLA experience. Cancer 59 (3 Suppl): 610–612PubMedCrossRefGoogle Scholar
  417. Satoh S, Tsuchiya N, Habuchi T, Ishiyama T, Seimo K, Katho T (2005) Renal cell and transitional cell carcinoma in Japanese population undergoing maintenance dialysis. J Urol 174: 1749–1753PubMedCrossRefGoogle Scholar
  418. Savage PD, Muss HB (1995) Renal cell cancer. In: De Vita VT, Hellman S, Rosenberg SA (eds) Biological Therapy of Cancr. Lippincott, Philadelphia, pp 373–387Google Scholar
  419. Schendel DJ, Gansbacher B (1993) Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes: modulation of recognition through retroviral transduction of tumor cells with interleukin 2 complementary DNA and exogenous alpha interfern treatment. Cancer Res 53 (17): 4020–4025PubMedGoogle Scholar
  420. Schlichter A, Wunderlich H, Junker K, Kosmehl H, Schubert J (1999) Limits for organ-preserving surgery in renal cell carcinoma. Urologe A. 1999 38: 479–85CrossRefGoogle Scholar
  421. Schlichter A, Wunderlich H, Junker K, Kosmehl H, Schubert J (2000) Where are the limits of elective nephron-sparing surgery in renal cell carcinoma? Eur Urol 37: 517–520PubMedCrossRefGoogle Scholar
  422. Schmidt L, Duh FM, Kishida T et al. (1997) Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 16: 68–73PubMedCrossRefGoogle Scholar
  423. Schmidt LS, Warren MB, Nickerson ML et al. (2001) Birt-Hogg-Dube syndrome, a genodermatosis associated with spontaneous pneumothorax and kidney neoplasia, maps to thromosome 17p11.2. Am J Hum Genet 69: 876–882PubMedCrossRefGoogle Scholar
  424. Schrader AJ, Olbert PJ, Hegele A, Varga Z, Hofmann R (2008) Metastatic non-clear cell renal cell carcinoma: current therapeutic option: BJU Int 101 (11): 1343–1345PubMedCrossRefGoogle Scholar
  425. Schraml P, Hergovich A, Hatz F, Amin MB, Lim SD, Krek W, Mihatsch MJ, Moch H (2003) Relevance of nuclear and cytoplasmic von hippel lindau protein expression for renal carcinoma progression. Am J Pathol 163:1013–1020PubMedGoogle Scholar
  426. Schrodter S, Hakenberg OW, Manseck A, Leike S, Wirth MP (2007) Outcome of surgical treatment of isolated local recurrence after radical nephrectomy for renal cell carcinoma. J Urol 167: 1630–3CrossRefGoogle Scholar
  427. Sella A, Swanson DA, Ro JY, Putnam JB Jr, Amato RJ, Markowitz AB, Logothetis CJ (1993) Surgery following response to interferon-alphabased therapy for residual renal cell carcinoma. J Urol 49: 19–21Google Scholar
  428. Semelka RC, Shoenut JP, Magro CM, Kroeker MA, MacMahon R, Greenberg HM (1993) Renal cancer staging: comparison of contrastenhanced CT and gadolinium-enhanced fat-suppressed spinecho and gradient-echo MR imaging. J Magn Reson Imaging 3: 597–602PubMedCrossRefGoogle Scholar
  429. Shalev M, Cipolla B, Buille F, Staerman E, Lobel B (1995) Is ipsilateral adrenalectomy a necessary component of radical nephrectomy? J Urol 153: 1415PubMedCrossRefGoogle Scholar
  430. Sherry RM, Pass HI, Rosenberg SA, Yang JC (1992) Surgical resection of metastatic renal cell carcinoma and melanoma after response to interleukin-2-based immunotherapy. Cancer 69: 1850–1855PubMedCrossRefGoogle Scholar
  431. Sheth S, Scatarige JC, Horton KM et al. (2001) Current concepts in the diagnosis and management of renal cell carcinoma. role of multi-detector CT and three-dimensional CT. Radiographics 21: 237Google Scholar
  432. Shimizu M, Yokota J, Mori N et al. (1990) Introduction of normal chromosome 3p modulates the tumorgenicity of a human renal cell carcinoma cell line YCR. Oncogene 5: 185–194PubMedGoogle Scholar
  433. Shingleton WB, Sewell PE (2001) Percutaneous cryoablation of renal tumors with magnetic resonance imaging guidance. J Urol 167: 1268–1270CrossRefGoogle Scholar
  434. Shuin T, Kondo K, Torigoe S et al. (1994) Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. Cancer Res 54: 2852–5PubMedGoogle Scholar
  435. Shvarts O, Tsui KH, Smith RB, Kernion JB, Belldegrun A (2000) Blood loss and the need for transfusion in patients who undergo partial or radical nephrectomy for renal cell carcinoma. J Urol 164 (4): 1160–3PubMedCrossRefGoogle Scholar
  436. Siemer S, Lehmann J, Kamradt J et al. (2004) Adrenal metastases in 1635 patients with renal cell carcinoma. outcome and indication for adrenalectomy. J Urol 171: 2155–2159PubMedCrossRefGoogle Scholar
  437. Siminovitch JP, Montie JE, Straffon RA (1982) Lymphadenectomy in renal adenocarcinoma. J Urol 127: 1090PubMedGoogle Scholar
  438. Simons J (1995) Phase I study of nun-replicating autologous tumor cell injections using cells prepared with or without GM-CSF gene transduction in patients with metastatic renal cell carcinoma. Hum Gene Ther 6: 347–368CrossRefGoogle Scholar
  439. Skinner DG, Colvin RB, Vermillon CD, Pfister RC, Leadbetter WI (1971) Diagnosis and management of renal cell carcinoma. Cancer 8: 1165–1177CrossRefGoogle Scholar
  440. Sorbellini M, Kattan MW, Snyder ME, Reuter V, Motzer R, Goetzl M; McKiernan J, Russo P (2005) A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. J Urol 173 (1): 48–51PubMedCrossRefGoogle Scholar
  441. Sowery RD, Siemens DR (2004) Growth characteristics of renal cortical tumors in patients manged by watchful waiting. Can J Urol 11: 2407–2410PubMedGoogle Scholar
  442. Spiegel DM, Yuen-Ko JL, Hou SH, Brandt TD, Grant TH (1991) Incidence of renal cell carcinoma and natural history of acquired renal cystic desease in end-stage renal disease. Am J Nephrol 11: 166–167PubMedCrossRefGoogle Scholar
  443. Stadler WM, Huo D, George C, Yang X, Ryan CW, Karrison T, Zimmerman T, Vogelzang NJ (2003) Prognostic factors for survival with gemcitabine plus 5-fluorocil based regimens for metastatic renal cancer. J Urol 170: 1141–1145PubMedCrossRefGoogle Scholar
  444. Staehler G, Drehmer I, Pomer S (1994) Tumorbefall der Vena cava beim Nierenzellkarzinom. Urologe A 33: 116–121PubMedGoogle Scholar
  445. Steiner T, Knels R, Schubert J (2004) Prognostic significance of tumour size in patients after tumour nephrectomy for localised renal cell carcinoma. Eur Urol 46: 327–330PubMedCrossRefGoogle Scholar
  446. Stephenson AJ, Hakimi AA, Snyder ME, Russo P. (2004) Complications of radical and partial nephrectomy in a large contemporary cohort. J Urol 171 (1): 130–4PubMedCrossRefGoogle Scholar
  447. Stief CG, Jahne J, Hagemann JH, Kuczyk M, Jonas U (1997) Surgery for metachronous solitary liver metastases of renal cell carcinoma. J Urol 158: 375–7PubMedCrossRefGoogle Scholar
  448. Stifelman MD, Handler T, Nieder AM, Del Pizzo J, Taneja S, Sosa RE, Shichman SJ (2003) Hand-assisted laparoscopy for large renal specimens: a multi-institutional study. Urology. 61: 78–82PubMedCrossRefGoogle Scholar
  449. Stillwell, TJ, Gomez MR, Kelalis PP (1987) Renal lesions in tuberous sclerosis. J Urol 138: 447Google Scholar
  450. Stolle CA, Glenn G, Zbar B et al. (1998) Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gne. Human Mutation 12: 417–23PubMedCrossRefGoogle Scholar
  451. Störkel S, Ebie JN, Adlakha K et al. (1997) Classification of renal cell carcinoma: workgroup no. 1, Union Internationale Contre le Cancer (UICG) and the American Joint Committee on Cancer (AJCC). Cancer 80: 987–989PubMedCrossRefGoogle Scholar
  452. Störkel S, Thoenes W, Jacobi GH, Engelmann U, Lippold R (1990) Prognostic parameters of renal cell carcinoma. Eur Urol 18 (2): 36–37PubMedGoogle Scholar
  453. Strohmeyer TG, Slamon DJ (1994) Proto-oncogenes and tumor suppressor genes in human urological malignancies. J Urol 151: 1479–1497PubMedGoogle Scholar
  454. Studer UE, Scherz S, Scheidegger J, Kraft R, Sonntag R, Ackermann D, Zingg EJ (1990) Enlargement of regional nodes in renal cell carcinoma i soften not due to metastases. J Urol 144: 243–245PubMedGoogle Scholar
  455. Su LM, Jarrett TW, Chan DY, Kavoussi LR, Solomon SB (2003) Percutaneous computed tomography — guided radiofrequency ablation of renal masses in high surgical risk patients. Preliminary results. Urology 61: 26–33CrossRefGoogle Scholar
  456. Sükösd F, Digon B, Fischer J, Pietsch T, Kovacs G (2001) Allelic loss at 10q23.3 but lack of mutation of PTEN/MMAC1 in chromophobe renal cell carcinoma. Cancer Genet Cytogenet 128: 161–163PubMedCrossRefGoogle Scholar
  457. Sutherland SE, Resnik MI, MacLennan GT, Goldman HB (2002) Does the size of the surgical margin in partial nephrectomy for renal cell cancer really matter. J Urol 167: 61–64PubMedCrossRefGoogle Scholar
  458. Swanson DA, Borges PM (1983) Complications of transabdominal radical nephrectomy for renal cell carcinoma. J Urol 129: 704–707PubMedGoogle Scholar
  459. Szczylik G, Demkow T, Stähler M et al. (2007) Randomized phase II traial of first-line treatment with sorafenib versus interferon in patients with advandes renal cell cardinoma. final results. Proc Am Soc Clin Oncol J Clin Oncol 25: 5025Google Scholar
  460. Takatera H, Maeda O, Toshirsugu O et al. (1986) Solitary later recurrence of renal cell carcinoma. J Urol 136: 799–801PubMedGoogle Scholar
  461. Talberg T, Tykkä H, Mahlberg K, Haltunnen P, Lehtonen I, Kalima I, Sama S (1985) Active specific immunotherapy with supportive measures in the treatment of palliatevely nephrectomized renal adenocarcinoma patients. A thirteen-year follow-up study. Eur Urol 11: 233–243Google Scholar
  462. Tamai H, Takiguchi Y, Oka M, Shingaki N, Enomoto S, Shiraki T, Furuta M, Inoue I, Iguchi M, Yanaoka K, Arii K, Shimizu Y, Nakata H, Shinka T, Sanke T, Ichinose M (2005) Contrast-enhanced ultrasonography in the diagnosis of solid renal tumors. J Ultrasound Med. 24: 1635–40PubMedGoogle Scholar
  463. Tammela ILJ, Leinomen ASS, Konturi MJ (1991) Comparison excretory urography, angiography, ultrasound and computed tomography for I category staging of renal cell carcinoma. Scand J Urol Neprhol 25: 283–286CrossRefGoogle Scholar
  464. Tamaskar H, Garcia JA, Elson P Wood L, Mekhail T, Dreicer R, Rini BI, Bukowski RM (2008) Antitumor effects of sunitinib of sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J Urol 179: 81–86PubMedCrossRefGoogle Scholar
  465. Terrone C, Guercio S, De Luca S, et al. (2003) The nunmber of lymph nodes examined and staging accuracy in renal cell carcinoma. BJU Int 91: 37–40PubMedCrossRefGoogle Scholar
  466. Terrone C, Gontero P, Volpe A, Porpiglia F, Bollito E, Zattoni F, Frea B, Tizzani A, Fontana D, Scarpa RM, Rossetti SR (2008) Proposal of an improved prognostic classification for pT3 renal cell carcinoma. J Urol 180: 72–78PubMedCrossRefGoogle Scholar
  467. Taneja SS, Pierce WW, Figlin R, Belldegrun A (1994) Management of disseminated kidney disease. Urol Clin North Am 21: 625–637PubMedGoogle Scholar
  468. Tanguay S, Swanson DA, Putnam JB (1996) Renal cell carcinoma metastatic to the lung: potential benefit in the combination to biological therapy and surgery. J Urol 156: 1586–1589PubMedCrossRefGoogle Scholar
  469. Tate R, Iddenden R, Harnden P, Morris E, Craigs C, Bennett C, Brook C, Haward RA, Forman D (2003) Increased incidence of renal parenchymal carcinoma in the Northern and Yorkshire region of England, 1978–1997. Eur J Cancer 39 (7): 961–7PubMedCrossRefGoogle Scholar
  470. Terrone C, Cracco C, Guercio S, Bollito E, Poggio M, Scoffone C, Tarabuzzi R, Porpiglia F, Scarpa RM, Fontana D, Rocca Rossetti S (2004) Prognostic value of the involvement of the urinary collecting system in renal cell carcinoma. Eur Urol 46: 472–6PubMedCrossRefGoogle Scholar
  471. Tomlinson IP, Alam NA, Rowan AJ, Barclay E, Jaeger EE, Kelsell D, Leigh I, Gorman P, Lamlum H, Rahman S, Roylance RR, Olpin S, Bevan S, Barker K, Hearle N, Houlston RS, Kiuru M, Lehtonen R, Karhu A, Vilkki S, Laiho P, Eklund C, Vierimaa O, Aittomäki K, Hietala M, Sistonen P, Paetau A, Salovaara R, Herva R, Launonen V, Aaltonen LA; Multiple Leiomyoma Consortium (2002) Germline, mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Gent 30: 1–5CrossRefGoogle Scholar
  472. Thoenes W, Störkel S, Rumpelt HJ (1986) Histopathology of renal cell tumors (adenomas, oncocytomas and carcinomas): the basic cytological and histopathological elements and their use for diagnostics. Pathol Res Pract 181: 125–143PubMedGoogle Scholar
  473. Thompson IM, Peek M (1988) Improvement in survival of patients with renal cell carcinoma — the role of the serendipitously detected tumor. J Urol 140: 187–190Google Scholar
  474. Thompson RH, Leibovich BC, Lohse CM, Cheville JC, Zincke H, Blute ML, Frank I (2007) Dynamic outcome prediction in patients with clear cell carcinoma treated with radical nephrectomy: the D-SSIGN score. J Urol 177: 477–480PubMedCrossRefGoogle Scholar
  475. Thrasher JB, Robertson JE, Paulson DF (1994) Expanding indications for conservative renal surgery in renal cell carcinoma. Urology 43: 160–168PubMedCrossRefGoogle Scholar
  476. Tolia BM, Whitmore WF Jr. (1975) Solitary metastasis from renal cell carcinoma. J Urol 114: 836–8PubMedGoogle Scholar
  477. Toro JR, Nickerson ML, Wie MH et al. (2003) Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in north america. Am J Hum Genet 73: 95–106PubMedCrossRefGoogle Scholar
  478. Tosaka A, Ohya K, Yamada K, Ohashi H, Kitahara S, Sekine H, Takehara Y, Oka K (1990) Incidence and properties of renal massas and asymptomatic renal cell carcinoma detected by abdominal ultrasonogrpahy. J Urol 144: 1097–1099PubMedGoogle Scholar
  479. Tourani JM, Pfister C, Berdah JF et al. (1998) Outpatient treatment with subcutaneous interleukin-2 and interferon alfa administration in combination with fluorouracil in patients with metastatic renal cell carcinoma: results of a sequential nonrandomized phase II study. Subutaneous Administration Propeukin Program Cooperative Group. J Clin Oncol 16: 2505–2513PubMedGoogle Scholar
  480. Tsui KH, Shvarts O, Barbaric Z et al. (2000) Is adrenalectomy a necessary component auf radical nephrectomy: UCLA experience with 511 radical nephrectomies. J Urol 163: 437–441PubMedCrossRefGoogle Scholar
  481. Tunuguntla HSGR, Jorda M (2008) Diagnostic and prognostic molecular markers in renal cell carcinoma. J Urol 179: 2096–2102PubMedCrossRefGoogle Scholar
  482. Turna B, Frota R, Kamoi K, Lin YC, Aron M, Desai MM, Kaouk JH, Gill IS (2008) Risk factor analysis of postoperative complications in laparoscopic partial nephrectomy. J Urol 179: 1289–1295PubMedCrossRefGoogle Scholar
  483. Tykkä H, Oravisto KJ, Lehtonen T, Sarna S, Tallberg T (1978) Active specific immunotherapy of advanced renal cell carcinoma. Euro Urol 4: 250–258Google Scholar
  484. Ueda T, Yasumasu T, Uozomi J, Naito S (1991) Comparison of clinical and pathological characteristics in incidentally detected and suspected renal carcinoma. Br J Urol 68: 470–472PubMedCrossRefGoogle Scholar
  485. Unnithan JS, Choueiri T, Garcia J, Dreicer R, Laura W, Bukowski R, Rini B (2007) Safety of VEGF-targeted tyrosine kinase inhibitors in patients (Pts) with metastatic remal cell carcinoma (mRCC) and central nervous system (CNS) metastases. J Clin Urol ASCO 25: 18S: 5047Google Scholar
  486. Uzzo RG, Cherullo EE, Myles J, Novick AC (2002) Renal cell carcinoma invading the urinary collecting system: implications for staging. J Urol. 167: 2392–6PubMedCrossRefGoogle Scholar
  487. Uzzo RG (2005) Renal cell carcinoma: urologists in a new era. J Urol 174: 1723–1724PubMedCrossRefGoogle Scholar
  488. Valle L, Cascon A, Melchor L, Otero I, Rodriguez-Perales S, Sanchez L, Cruz Cigudosa J, Robledo M, Weber B, Urioste M, Benitez J (2005) About the origin and development of hereditary conventional renal cell carcinoma in a four-generation t (3: 8) (p14.1: q24.23) family. Eur J Hum Genet 13 (5): 570–8PubMedCrossRefGoogle Scholar
  489. van Kessel AG, Wijnhoven H, Bodmer D, Eleveld M, Kiemeney L, Mulders P, Weterman M, Ligtenberg M, Smeets D, Smits A (1999) Renal cell cancer: chromosome 3 translocations as risk factors. J Nat Cancer Inst 91: 1159–1160PubMedCrossRefGoogle Scholar
  490. Van Poppel H, Claes H, Willemen P, Oyen R, Baert I (1991) Is there a place for conservative surgery of renal carcinoma? Br Urol 67: 129–133CrossRefGoogle Scholar
  491. van Poppel H, Da Pozzo L, Albrecht W, Matveev V, Bono A, Borkowski A, Marechal JM, Klotz L, Skinner E, Keane T, Claessen I, Sylvester R (2007) A prospective randomized EORTC Intergroup Phase 3 Study Comparing the Complications of Elective Nephron-Sparng Surgery and Radical Nephrectomy for Low-Stage Renal Cell Carcinoma. Eur Urol 51: 1606–1615.PubMedCrossRefGoogle Scholar
  492. Volpe A, Panzarella T, Rendon RA, Haider MA, Kondylis FI, Jewett MA (2004) The natural history of incidentelly detected small renal masses. Cancer 100: 738–745PubMedCrossRefGoogle Scholar
  493. Volpe A, Kachura JR, Geddie WR, et al. (2007) Techniques, safety and accuracy of sampling of renal tumors by fine needle aspiration and core biopsy. J Urol 178: 379–386PubMedCrossRefGoogle Scholar
  494. Vasudevan A, Davies RJ, Shannon BA, Cohen RJ (2006) Incidental renal tumors: the frquency of benign lesions and the role of preoperative core biopsy. BJU International 97: 946–949PubMedCrossRefGoogle Scholar
  495. Viterbo R, Chawla S, Crispen P et al. (2005) Delayed management of incidentally detected renal masses does not limit or cimplicate treatment options. J urol 173: 23A82Google Scholar
  496. Volkmer BG, Gschwend JE (2002) Value of metastases surgery in metastic renal cell carcinoma. Urologe A 41: 225–230PubMedCrossRefGoogle Scholar
  497. Volpe A, Panzarella T, Rendon RA, Haider MA, Kondylis FI, Jewett MAS (2004) The natural history of incidentally detected small renal masses. Cancer 100 (4): 738–745PubMedCrossRefGoogle Scholar
  498. von Knobloch R, Hegele A, Kälble T, Hofmann R (2000) Management of contralateral adrenal metastasis from renal cell carcinoma: possibility of inferior vena cava tumour thrombus. Scand J Urol Nephrol 34: 109–113CrossRefGoogle Scholar
  499. Waers JS, Moss C, Hackett S et al. (2003) A phase II trial of gemcitabine (GEM) plus cepecitabine (CAPE) in patients with metastatic renal cell carcinoma (mRCC). Proc Am Soc Clin Oncol 22: 386 (Abstr 1549)Google Scholar
  500. Walther MM, Lubensky IA, Venzon D, Zbar B, Linehan WM (1995) Prevalence of microscopic lesions in grossly normal renal parenchyma from patients with von Hippel-Lindau disease, sporadic renal cell carcinomaand no renal disease: Clinical implications. J Urol 154: 2010–5PubMedCrossRefGoogle Scholar
  501. Washecka R, Hanna M (1991) Malignant renal tumors in tuberous sclerosis. Urology 4: 340–343CrossRefGoogle Scholar
  502. Washio M, Mori M, Sakauchi F, Watanabe Y, Ozasa K, Hayashi K, Miki T, Nakao M, Mikami K, Ito Y, Wakai K, Tamakoshi A, JACC Study Group (2005) Risk factors for kidney cancer in a Japanese population: findings from the JACC Study. J Epidemiol 15 (Suppl 2): s203–11CrossRefGoogle Scholar
  503. Waters JS, Moss C, Pyle L, James M, Hackett S, A’hern R, Gore M, Eisen T (2004) Phase II clinical trial of capecitabine and gemcitabine chemotherapy in patients with metastatic renal carcinoma. Brit J Cancer 91: 1763–1768PubMedCrossRefGoogle Scholar
  504. Weaver DJ, Michalski K, Miles J (1989) Cytogenetics of bileratal renal cell carcinoma. J Urol 142: 497–700Google Scholar
  505. Wehle MJ, Thiel DD, Petrou SP, Young PR, Frank I, Karsteadt N (2004) Conservative management of incidental contrast enhancing renal masses as safe alternative to invasive therapy. Urology 64 (1): 49–52PubMedCrossRefGoogle Scholar
  506. Weight CJ, Kaouk JH, Hegarty NJ, Remer EM, O’Malley CM, Lane BR, Gill IS, Novick AC (2008) Correlation of radiographic imaging and histopathology following cryoablation and radio frequency ablation for renal tumors. J Urol 179: 1277–1283PubMedCrossRefGoogle Scholar
  507. Weikert S, Boeing H, Pischon T, Weikert C, Olsen A, Tjonneland A, Overvad K, Becker N, Linseisen J, Trichopoulou A, Mountokalakis T, Trichopoulos D, Sieri S, Palli D, Vineis P, Panico S, Peeters PHM, Bueno-de-Mesquita HB, Verschuren WMM, Ljungberg B, Hallmans G, Berglund G, Gonzales CA, Dorronsoro M, Barricarte A, Tormo MJ, Allen N, Roddam A, Bingham S, Khaw KT Rinaldi S, Ferrari P, Norat T, Riboli E (2008) Blood pressure and risk of renal cell carcinoma in the european prospective investigation into cancer and nutrition. Am J Epidemiol 167: 438–446PubMedCrossRefGoogle Scholar
  508. Weinblatt ME, Kahn E, Kochen J (1987) Renal cell carcinoma in patients with tuberous sclerosis. Pediatrics 80: 898PubMedGoogle Scholar
  509. Weirich G, Glenn G, Junker K et al. (1998) Familial renal oncocytoma: clinicopathological study of 5 families. J Urol 160: 335–340PubMedCrossRefGoogle Scholar
  510. West WH, Tauer KW, Yanelli IR, Marshall GD, Ott DW, Thurman B, Oldham RK (1987) Constant-infusion of recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 316: 898–905PubMedCrossRefGoogle Scholar
  511. Wierecky J, Müller M, Brossat P (2006) Dendritic cell-based cancer immunotherapy targeting MUC-1. Cancer Immunol Immunother 55 (1): 63–67PubMedCrossRefGoogle Scholar
  512. Wiesner C, Jakse G, Rohde D (2002) Therapy of local recurrence of renal cell carcinoma. Oncol Rep 9: 189–92PubMedGoogle Scholar
  513. Winter P, Miersch WD, Vogel J, Jaeger N (1990) On the nedessity of adrenal extirpation combined with radical nephrectomy. J Urol 144: 842–844PubMedGoogle Scholar
  514. Wirth M (1991) Stellenwert der Interferone, des Interleukin 2 und des Tumornekrosefaktors in der Therapie des Nierenzellkarzinoms. Urologe A 30: 77–80PubMedGoogle Scholar
  515. Wood L, Bukowski RM, Dreicer R, Elson P, Garcia JA, Gilligan T, Mekhail T, Rini BR (2008) Temsiroslismus (TEM) in metastatic renal cell carcinoma (mRCC): Safetey and efficacy in patients previously treated with VEGF-targeted therapy. ASCO A353Google Scholar
  516. Woodward ER et al. (2000) Familial clear cell renal cell carcinoma (FCRC): clinical features and mutation analysis of the VHL, MET, and CUL2 candidate genes. J Med Genet 37: 348–353PubMedCrossRefGoogle Scholar
  517. Woodward ER, Clifford SC, Astuti D, Affara NA, Maher ER (2000) Familial clear cell renal cell carcinoma (FCRC): clinical features and mutation analysis of the VHL, MET, and CUL2 candidate genes. J Med Genet 37: 348–353PubMedCrossRefGoogle Scholar
  518. Wotkowicz C, Libertino JA, Sorcini A, Mourtzinos A (2006) Management of renal cell carcinoma with vena cava and trial thrombus minimal access vs median sternotomy with circulatory arrest. BJU Int 98: 289–297PubMedCrossRefGoogle Scholar
  519. Yang JC, Haworth L, Sherry RM, Hwu P, Schwarzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA (2003) A randomized trial of bevacizumab, an antivascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349 (5): 427–434PubMedCrossRefGoogle Scholar
  520. Yaycioglu O, Roberts WW, Chan T, Epstein JI, Marshall FF, Kavoussi LR (2001) Prognostic assessment of nonmetastic renal cell carcinoma: a clinically based model. Urology 58 (2): 141–145PubMedCrossRefGoogle Scholar
  521. Yossepowitsch O, Thompson RH, Leibovich BC, Eggener SE, Pettus JA, Kwon ED, Herr HW, Blute ML, Russo L (2008) Positive surgical margins at partial nephrectomy: predictors and oncological outcomes. J Urol 179: 2158–2163CrossRefGoogle Scholar
  522. Yuan J-M, Castealo JE, Gago-Dominguez M, Ross RK, Yu MC (1998) Hypertension obesity and their medications in relatation to renal cell carcinoma. Br J Cancer. 77: 1508–1513PubMedGoogle Scholar
  523. Zbar B, Tory K, Marino M et al. (1994) Hereditary papillary renal cell carcinomas. J Urol 151: 561PubMedGoogle Scholar
  524. Zbar B, Glenn G, Lubensky IA et al. (1995) Hereditary papillary renal cell carcinoma: clinical studies in 10 families. J Urol 153: 907–12PubMedCrossRefGoogle Scholar
  525. Zincke H, Sen SE (1988) Experience with extracorporal surger and autotransplantation for renal cell and transitional cell cancer of the kidney. J Urol 140 (1): 25–27PubMedGoogle Scholar
  526. Zisman A, Pantuck AJ, Wieder J, Chao DH, Dorey F, Said JW, deKernion JB, Figlin RA, Belldegrun AS (2002) Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol 20: 4559–4566PubMedCrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag Heidelberg 2009

Authors and Affiliations

  • Gerhard Jakse
    • 1
  • Axel Heidenreich
    • 2
  • Marcus Schenck
    • 3
  1. 1.Aubel
  2. 2.Urologische KlinikUniversitätsklinikum der RWTH AachenAachen
  3. 3.Klinik für UrologieUniversitätsklinikum EssenEssen

Personalised recommendations